<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0011.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0013.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h84" class="calibre8"></a><a id="page_6-1" class="calibre8"></a><a href="part0003.html#rh93" class="calibre8">PNEUMONIA</a></h2>
<p class="h">Definitions and clinical manifestations</p>
<p class="noindent1">• Pneumonia: s/s (fever, cough, purulent sputum, dyspnea) + new infiltrate on chest imaging</p>
<p class="noindent1">• Community-acquired pneumonia (CAP): pneumonia acquired outside of hospital setting</p>
<p class="noindent1">• Hospital-acquired pneumonia (HAP): pneumonia acquired ≥48 hrs after hospitalization</p>
<p class="noindent1">• Ventilator-associated pneumonia (VAP): pneumonia acquired ≥48 hrs after intubation</p>
<p class="noindent1">• Lung empyema: accumulation of pus in pleural space</p>
<p class="noindent1">• Lung abscess: parenchymal necrosis with confined cavitation</p>
<p class="noindent1">• Aspiration pneumonitis: acute lung injury after inhalation of gastric contents without infection, though bacterial infection can occur within 24–72 hrs of injury</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Microbiology of Pneumonia</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Clinical Setting</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">CAP</b> <span class="sm">(<i class="calibre6">AJRCC</i> 2019;200:7)</span></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">No pathogen identified in 50–60%</i>, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in &lt;5%</p>
<p class="tbody">Viruses: influenza, RSV, hMPV, parainfluenza, rhinovirus, coronavirus</p>
<p class="tbody"><i class="calibre6">S. pneumoniae</i> (most common bacterial cause)</p>
<p class="tbody"><i class="calibre6">S. aureus</i> (espec. post-influenza)</p>
<p class="tbody"><i class="calibre6">Mycoplasma</i>, <i class="calibre6">Chlamydia</i> (espec. in young &amp; healthy)</p>
<p class="tbody"><i class="calibre6">H. influenzae, M. catarrhalis</i> (espec. in COPD)</p>
<p class="tbody"><i class="calibre6">Legionella</i> (espec. in elderly, smokers, ↓ immunity, TNF inhibitors)</p>
<p class="tbody"><i class="calibre6">Klebsiella</i> &amp; other GNR (espec. in alcoholics &amp; aspiration)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">HAP/VAP</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">S. aureus, Pseudomonas, Klebsiella, E. coli, Enterobacter, Acinetobacter, Steno</i>. IV abx w/in 90 d risk factor for MDR. Viral ~20% cases.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Empyema</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">S. pneumo, S. aureus, E. coli</i>, <i class="calibre6">Klebsiella</i>, <i class="calibre6">H. influenzae</i>, anaerobes</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Lung abscess</b></p></td>
<td class="th1"><p class="tbody">Often polymicrobial, incl. oral flora. <i class="calibre6">S. aureus,</i> anaerobes<i class="calibre6">, Strep</i> (<i class="calibre6">anginosus,</i> GAS), GNR <i class="calibre6">(Klebsiella, E. coli, Pseudomonas), Nocardia, Actinomyces,</i> fungi, mycobacteria, <i class="calibre6">Echinococcus</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Immunosupp.</b></p></td>
<td class="th1"><p class="tbody">Above + <i class="calibre6">Pneumocystis</i>, <i class="calibre6">Cryptococcus</i>, <i class="calibre6">Nocardia</i>, non-TB myco- bacteria (NTM), CMV, invasive molds</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">AJRCC</span> <span class="r1">2019;200:e45)</span></p>
<p class="noindent1">• <b class="calibre7">Sputum Gram stain/Cx:</b> reliable if high quality (ie, sputum not saliva; &lt;10 squam cells/lpf). If bacterial PNA should be purulent (&gt;25 PMN/lpf). Yield ↓ &gt;10 h after abx <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2014;58:1782)</span>.</p>
<p class="noindent1">• <b class="calibre7">Procalcitonin:</b> ↑ in acute bacterial (not viral) PNA. Consider stopping abx if levels &lt;0.25 ng/ml (&lt;0.5 ng/mL in ICU Pts) or ↓ ≥80% from peak. ↓ abx exposure by 2–3 d <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">ID 2016;16:819 &amp; 2018;18:95)</span>. Not validated in immunosuppressed hosts. Levels harder to interpret in CKD. False ⊕ in cardiac arrest, shock, burns, surgery.</p>
<p class="noindent1">• <b class="calibre7">CXR</b> (PA &amp; lateral; see Radiology inserts)</p>
<p class="noindent1">• HIV test (if unknown); MRSA nares swab in HAP/VAP (if ⊖ 96% NPV for MRSA PNA)</p>
<p class="noindent1">• Consider in severe disease (otherwise not recommended):</p>
<p class="noindent2"><i class="calibre6">Legionella</i> urinary Ag (detects <i class="calibre6">L. pneumophila</i> L1 serotype, 60–70% of clinical disease)</p>
<p class="noindent2"><i class="calibre6">S. pneumoniae</i> urinary Ag (Se 70%, Sp &gt;90%)</p>
<p class="noindent2">Blood cultures (<i class="calibre6">before antibiotics!</i>): ⊕ in ~10% of inPts, depending on pathogen</p>
<p class="noindent1">• If clinical suspicion for mTB: (induced) sputum AFB stain ×3 q ≥8h (w/ ≥1 early morning). Mycobact. cx (<i class="calibre6">empiric respiratory isolation while pending</i>); MTb DNA PCR if smear ⊕.</p>
<p class="noindent1">• <b class="calibre7">Viral testing</b> (DFA or PCR) on nasopharyngeal swab or sputum</p>
<p class="noindent1">• Bronchoscopy: immunosupp., critically ill, failure to respond, suspected PCP, inadequate/ ⊖ sputum cx (send Gram stain/cx, <i class="calibre6">Legionella</i> cx, fungal cx/wet prep, mycobacterial cx/smear, modified AFB stain, galactomannan)</p>
<p class="noindent1">• Reasons for failure to improve on initial treatment:</p>
<p class="noindent2">Insufficient time: may take ≥72 h to see improvement (fever persists &gt;4 d in ~20%)</p>
<p class="noindent2">Insufficient drug levels for lung penetration (eg, vanco trough &lt;15–20 μg/mL)</p>
<p class="noindent2">Resistant organisms or superinfxn: eg, MRSA, <i class="calibre6">Pseudo.;</i> consider <b class="calibre7">bronchoscopy</b></p>
<p class="noindent2">Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; <b class="calibre7">consider CT</b></p>
<p class="noindent2">Parapneumonic effusion/empyema/abscess: if CXR ⊖, <b class="calibre7">consider bedside US or CT</b>. If effusion &gt;1 cm, drain &amp; send fluid pH, gluc, Gram stain &amp; Cx.</p>
<p class="noindent2">Metastatic infection (eg, endocarditis, septic arthritis)</p>
<p class="h">Triage</p>
<p class="noindent1">• <b class="calibre7">qSOFA</b> predicts poor outcomes, prolonged ICU stay, and in-hospital mortality if &gt;2 of 3: RR&gt;22, AMS, SBP&lt;100 <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016; 315:801)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment</b> <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:651; <i class="calibre6">AJRCC</i> 2019;200:e45)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Scenario</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Regimen</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">CAP (outPt)</b></p></td>
<td class="th1"><p class="tbody">Amoxicillin, azithro, or doxy (<i class="calibre6">avoid</i> latter two if &gt;25% resistance locally)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">CAP (ward)</b></p></td>
<td class="th1"><p class="tbody">[3<sup class="calibre27">rd</sup>-gen ceph + azithro] <i class="calibre6">or</i> levoflox; omadacycline ≈ FQ <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:517)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><a id="page_6-2" class="calibre4"></a><b class="calibre7">CAP (ICU)</b></p></td>
<td class="th1"><p class="tbody">3<sup class="calibre27">rd</sup>-gen ceph + azithro. Only cover MRSA or <i class="calibre6">Pseudomonas</i> if risk factors (prior PsA PNA, MRSA infection, recent hospitalization, IV abx)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">HAP/VAP</b></p></td>
<td class="th1"><p class="tbody">[Pip-tazo <i class="calibre6">or</i> cefepime <i class="calibre6">or</i> carbapen.] + [vanc or linezolid]. May add resp FQ or azithro if concerned for atypicals. Daptomycin not active in lungs.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Empyema/ abscess</b></p></td>
<td class="th1"><p class="tbody">[3<sup class="calibre27">rd</sup>-gen ceph + MNZ] <i class="calibre6">or</i> amp-sulbactam. Only cover <i class="calibre6">Pseudomonas</i> or MRSA if risk factors. Empyema: drain if &gt;1 cm ± chest tube. Abscess: drainage not required. De-escalate to PO abx based on clinical improvement &amp; micro.</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Avoid quinolones if suspect TB. When possible, de-escalate abx based on sensitivities.</p>
<p class="noindent1">• Steroids: not unless indicated for shock or COPD exacerbation; may ↓ mortality, mech vent, &amp; ARDS in severe CAP <span class="r1">(</span><span class="r2">Cochrane</span> <span class="r1">2017;12:CD007720)</span>. <i class="calibre6">Avoid</i> in influenza.</p>
<p class="noindent1">• Duration: CAP: 5–7 days, can de-escalate IV abx to PO after clinical improvement. HAP/VAP: 7 days. Empyema/abscess: 2–6 wks based on complexity, drainage.</p>
<p class="h">Prevention</p>
<p class="noindent1">• All persons &gt;65 or age 19–64 w/ CHF, lung disease, cirrhosis, DM, EtOH, smoker, immunosupp. (eg, ESRD, organ transplant, HIV, leukemia, lymphoma, asplenia)</p>
<p class="noindent1">• PCV20 vaccine or PCV15 + PPSV23 1 yr later</p>
<p class="h1cr">V<small class="calibre31">IRAL</small> R<small class="calibre31">ESPIRATORY</small> I<small class="calibre31">NFECTIONS</small></p>
<p class="center"><i class="calibre6">URI, bronchitis, bronchiolitis, pneumonia</i> <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2011;377:1264)</span></p>
<p class="h">Microbiology &amp; epidemiology (<a href="http://www.cdc.gov/flu/weekly" class="calibre4">http://www.cdc.gov/flu/weekly</a>)</p>
<p class="noindent1">• Typical pathogens: Short, mild = rhinovirus, other non-SARS-CoV-2 coronavirus.</p>
<p class="noindent2">Longer, more severe or complicated = <b class="calibre7">influenza</b>, parainfluenza, RSV, adenovirus, metapneumovirus, COVID-19 (vide infra). Can be esp. severe in immunosupp.</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Sx: fever, cough, myalgias, SOB, wheezing, sore throat, rhinorrhea, malaise, confusion</p>
<p class="noindent1">• Respiratory viral panel on nasal swab or sputum/BAL; rapid flu <i class="calibre6">nasopharyngeal swab</i> preferred to nasal swab (Se 50–70%, Sp &gt;90%); RT-PCR for flu A/B (&gt;95% Se &amp; Sp)</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;390:697)</span></p>
<p class="noindent1">• <b class="calibre7">Influenza (A &amp; B):</b></p>
<p class="noindent1">• Neuraminidase inhib. (eg, oseltamivir); must start w/in 48 h of sx for low-risk; for critically ill or immunosupp., start ASAP even if &gt;48 h. Peramivir IV if unable to tolerate PO.</p>
<p class="noindent1">• Endonuclease inhib. (baloxavir), superior to oseltamivir in ↓ sx &amp; viral load on 1<sup class="calibre19">st</sup> day of Rx, but resistance emerging; no data in severe influenza <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018; 379:913)</span></p>
<p class="noindent1">• <b class="calibre7">RSV:</b> can consider inhaled ribavirin in immunosupp, but very expensive &amp; rarely used</p>
<p class="h">Prevention</p>
<p class="noindent1">• Inactivated <b class="calibre7">influenza vaccine</b>: rec for <i class="calibre6">all</i> &gt;6 mo of age.</p>
<p class="noindent1">• Isolation, droplet precautions for inpatients strongly recommended</p>
<p class="noindent1">• Ppx for high-risk contacts of confirmed influenza: oseltamivir × 7 d or baloxavir single dose</p>
<p class="h1cr">C<small class="calibre31">ORONAVIRUS</small> (COVID-19) / SARS-C<small class="calibre31">O</small>V-2 <small class="calibre31">INFECTION</small></p>
<p class="h">Microbiology &amp; epidemiology</p>
<p class="noindent1">• Person-to-person transmission via respiratory particles; asx &amp; pre-sx transmission can occur</p>
<p class="noindent1">• Incubation period: up to 14 days, median time of 4–5 days from exposure to sx onset</p>
<p class="h">Presentation</p>
<p class="noindent1">• Ranges from asx to severe illness. Of those with sx, 81% mild-to-moderate, 14% severe (hypoxia), 5% critical (ARDS, shock, multiorgan failure) <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020:323;13)</span></p>
<p class="noindent1">• Common sx: fever, chills, cough, dyspnea, myalgias, HA, N/V, diarrhea, loss of smell/taste</p>
<p class="noindent1">• Risk factors for severe illness: age ≥65, CVD, DM, stroke, lung dx, CKD, obesity</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• RT-PCR testing of nasopharynx, lower respiratory tract, or anterior nares</p>
<p class="noindent1">• Rapid antigen testing of anterior nares (less Se than PCR)</p>
<p class="noindent1">• CXR: typically bilateral opacities (esp peripheral), can be nl early; consider CT if dx ?</p>
<p class="h">Treatment <span class="r">(<a href="https://www.covid19treatmentguidelines.nih.gov/" class="calibre4">https://www.covid19treatmentguidelines.nih.gov/</a>)</span></p>
<p class="noindent1">• Non-hospitalized: mAb, paxlovid and molnupiravir if risk factors for severe disease</p>
<p class="noindent1">• Hospitalized w/ suppl O<sub class="calibre10">2</sub>: dexamethasone ± remdesivir (inhibits vRNA polymerase)</p>
<p class="noindent1">• Hospitalized w/ mechanical ventilation or ECMO: dexamethasone + anti IL6 (tocilizumab/ sarilumab) or anti JAK (baricitinib/tofacitinib) if rapidly ↑ O<sub class="calibre10">2</sub> requirement but not intubated</p>
<p class="noindent1">• Anticoag. due to high rate of thrombosis; Ppx vs. Rx dosing based on severity and risk</p>
<p class="h">Prevention</p>
<p class="noindent1">• Vaccines against spike protein highly effective. Infxn may occur but severity much lower.</p>
<p class="noindent1">• See CDC website for quarantine guidelines <span class="r1">(<a href="https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html" class="calibre4">https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html</a>)</span></p>
<h2 class="ct"><a id="h85" class="calibre8"></a><a id="page_6-3" class="calibre8"></a><a href="part0003.html#rh94" class="calibre8">FUNGAL INFECTIONS</a></h2>
<p class="h">Fungal diagnostics</p>
<p class="noindent1">• <b class="calibre7">Antigen detection</b></p>
<p class="noindent2"><b class="calibre7">1,3-β-D glucan</b> (Se 75%, Sp 85%): <b class="calibre7">Candida, Aspergillus, Histo, Coccidio, PCP</b>, <i class="calibre6">for invasive infxn in immunocomp host</i>. <i class="calibre6">Cannot</i> detect Mucor, Rhizopus, Blasto, Crypto.</p>
<p class="noindent2"><b class="calibre7">Galactomannan</b> (Se 71%, Sp 89%): <b class="calibre7">Aspergillus</b>. BAL preferred. Test <i class="calibre6">serum</i> only if heme malig or HSCT. Not for screening or Rx monitoring in solid organ Tx, chronic granulomatous disease (false ⊕ w/ colonization).</p>
<p class="noindent2"><b class="calibre7">Histo urine/serum Ag</b>: Se of urine Ag 90% (serum 80%) if dissem; Sp limited by X-react</p>
<p class="noindent2"><b class="calibre7">Crypto Ag</b> (serum, CSF): sAg &gt;90% Se &amp; Sp in invasive, less for pulm. only unless HIV+</p>
<p class="noindent2"><b class="calibre7">Blastomyces:</b> urine &gt;serum Ag, high Se but modest Sp given X-react w/ other fungi</p>
<p class="noindent1">• <b class="calibre7">Culture</b>: <i class="calibre6">Candida</i> grows in blood/urine Cx, but ↓ Se of BCx in deep tissue infection; others (eg, <i class="calibre6">Crypto</i>, <i class="calibre6">Histo</i>) ↓↓ Se of BCx; if suspect <i class="calibre6">Coccidio</i> alert lab <i class="calibre6">(biohazard)</i></p>
<p class="noindent1">• <b class="calibre7">Antibody detection</b>: useful for <i class="calibre6">Coccidio</i> (serum IgG and IgM 7–21 days post exposure)</p>
<p class="noindent1">• <b class="calibre7">Biopsy</b>: no grinding of tissue if Zygomycetes suspected</p>
<p class="h">Candida species</p>
<p class="noindent1">• <b class="calibre7">Microbiology:</b> normal GI flora; <i class="calibre6">C. albicans</i> &amp; nonalbicans spp.</p>
<p class="noindent1">• <b class="calibre7">Epidemiology:</b> neutropenia, immunosupp., broad-spectrum abx, intravascular catheters (esp. if TPN), IVDU, abd surgery, DM, renal failure, age &gt;65</p>
<p class="noindent1">• <b class="calibre7">Clinical manifestations:</b></p>
<p class="noindent2">Mucocutaneous: cutaneous (eg, red, macerated lesions in intertriginous zones); oral thrush (exudative, erythematous or atrophic; if unexplained, r/o HIV); esophageal (odynophagia; ± oral thrush); vulvovaginal, balanitis</p>
<p class="noindent2"><b class="calibre7">Candiduria:</b> typically <i class="calibre6">colonization</i> due to broad-spectrum abx and/or indwelling catheter</p>
<p class="noindent2"><b class="calibre7">Candidemia:</b> ⊕<i class="calibre6"> blood cx are never a contaminant!</i> R/o retinal involvement (ophtho consult) &amp; endocarditis w/ TTE ± TEE (esp. w/ prosthetic valve) as req ↑ Rx duration. May present w/ erythematous papules or pustules in immunosupp.</p>
<p class="noindent2">Candida in sputum: usually not a clinically significant pathogen</p>
<p class="noindent2"><b class="calibre7">Hepatosplenic:</b> typically, after prolonged neutropenia as cell counts are recovering</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment</b> <span class="sm">(<i class="calibre6">CID</i> 2016;62:409)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody">Mucocutaneous</p></td>
<td class="th1"><p class="tbody">Clotrimazole, nystatin, fluconazole, itraconazole</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Candiduria (<i class="calibre6">if pyuria or sx of infxn</i>)</p></td>
<td class="th1"><p class="tbody">Fluconazole or intravesical ampho if severe infxn,</p>
<p class="tbody">immunosupp. or planned GU procedure.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Candidemia w/o neutropenia</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Echinocandin</b> (mica 1<sup class="calibre27">st</sup> line) if stable w/o prior azole exposure can consider fluc; <i class="calibre6">remove CVC</i>; test for azole-resist.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Candidemia w/ neutropenia</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Echinocandin</b> <i class="calibre6">or</i> ampho; <i class="calibre6">remove CVC</i>; test for azole-resist.</p></td>
</tr>
</tbody>
</table>
<p class="h">Aspergillosis <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:499)</span></p>
<p class="noindent1">• <b class="calibre7">ABPA:</b> airway hypersensitivity secondary to aspergillus colonization</p>
<p class="noindent1">• <b class="calibre7">Chronic pulmonary aspergillosis:</b> includes aspergilloma (fungus ball), pulm. nodules, chronic cavitary and chronic fibrotic pulmonary aspergillosis that can present with subacute cough, dyspnea, hemoptysis; aspergilloma/nodules can be asymptomatic</p>
<p class="noindent1">• <b class="calibre7">Invasive aspergillosis:</b> seen in immunosupp., esp prolonged neutropenia. Primarily pulmonary, ie, PNA w/ <i class="calibre6">chest pain</i>, cough, <i class="calibre6">hemoptysis;</i> CT: solid/cavitary nodules, halo sign. Non-pulm. manifestations: rhinosinusitis (like Zygomycetes), CNS (brain abscesses, mycotic aneurysm), endophthalmitis (eye pain, visual changes), cutaneous, GI (typhlitis)</p>
<p class="noindent2">Rx: voriconazole or posaconazole preferred over ampho. For aspergilloma, ± resection.</p>
<p class="h">Zygomycetes <span class="r1">(eg,</span> <i class="calibre6">Mucor, Rhizopus</i><span class="r1">)</span></p>
<p class="noindent1">• <b class="calibre7">Epidemiology: diabetes</b> (espec. those w/ prior DKA), heme malignancy, neutropenia, transplant, chronic steroids, iron overload, trauma, h/o voriconazole Rx or Ppx</p>
<p class="noindent1">• <b class="calibre7">Clinical: rhinocerebral</b> = severe periorbital/facial pain, swelling, vision changes, sinusitis, opthalmoplegia, nasal ulcerations/ necrosis, HA. Other: <b class="calibre7">pulm.</b> (PNA w/ infarct &amp; necrosis); <b class="calibre7">cutaneous</b> (indurated painful cellulitis ± eschar); <b class="calibre7">GI</b> (necrotic ulcers); <b class="calibre7">renal</b> (flank pain, fever).</p>
<p class="noindent1">• <b class="calibre7">Treatment</b> (high mortality): 1st line is debridement + ampho. Can deescalate to posaconazole or isavuconazole if improving after debridement.</p>
<p class="h1cr">E<small class="calibre31">NDEMIC</small> F<small class="calibre31">UNGI</small></p>
<p class="h">Cryptococcus <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2010;50:291)</span></p>
<p class="noindent1">• <b class="calibre7">Epidemiology:</b> immunosupp. most susceptible (espec. AIDS, transplant recipients, and cirrhosis); can occur in healthy hosts (esp <i class="calibre6">C. gattii)</i></p>
<p class="noindent1">• <b class="calibre7">Clinical manifestations</b></p>
<p class="noindent2"><b class="calibre7">CNS</b> (meningoencephalitis): subacute HA, fever, meningismus, CN abnl, ± stupor</p>
<p class="noindent2">Other sites: pulm., GU, cutaneous, CNS cryptococcoma. <i class="calibre6">With any crypto dx, LP all Pts.</i></p>
<p class="noindent1"><a id="page_6-4" class="calibre4"></a>• <b class="calibre7">Dx:</b> CSF cell counts vary in HIV vs. non-HIV; serum/CSF CrAg (Se 99%, Sp 86–100%); cx</p>
<p class="noindent1">• <b class="calibre7">Treatment</b></p>
<p class="noindent2">CNS Rx has induction (ampho ± flucytosine × 2 wks), consolidation and maintenance (fluconazole) phases <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:1291)</span>; if ↑ ICP, may need repeat LP/VP shunt</p>
<p class="noindent2">Non-CNS disease (pulm., skin, bone, blood) in HIV ⊖ Pts: consider fluconazole</p>
<p class="h">Histoplasmosis <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2007;45:807)</span></p>
<p class="noindent1">• <b class="calibre7">Epidemiology</b>: endemic to central &amp; SE U.S., but sporadic cases throughout U.S.</p>
<p class="noindent1">• <b class="calibre7">Clinical manifestations</b></p>
<p class="noindent2">Acute: PNA ± hilar LAN, often subacute, but high inoculum can cause acute severe PNA</p>
<p class="noindent2">Chronic lung disease: cough + B sx ± cavitary lesions (Ddx TB, blasto)</p>
<p class="noindent2">Disseminated (seen in immunosupp.): fever, fatigue, wt loss, mucocutaneous lesions, ΔMS, arthritis, pericarditis, interstitial infiltrates HSN, LAN, cytopenias</p>
<p class="noindent1">• <b class="calibre7">Treatment:</b> mild to mod: itraconazole; disseminated/severe: ampho → itraconazole</p>
<p class="h">Coccidioidomycosis <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2016;63:112)</span></p>
<p class="noindent1">• <b class="calibre7">Epidemiology</b>: endemic to SW U.S., Central and South America</p>
<p class="noindent1">• <b class="calibre7">Clinical manifestations</b></p>
<p class="noindent2">Acute: subclinical PNA, arthralgias, rash (erythema nodosum)</p>
<p class="noindent2">Chronic lung disease (seen in immunosupp): dyspnea, chest pain, hemoptysis, “B” sx</p>
<p class="noindent2">Disseminated (immunosupp, pregnant): meningitis, osteo, monoarthritis, cutaneous</p>
<p class="noindent1">• <b class="calibre7">Treatment:</b> no Rx for mild PNA in immunosupp.; ampho for severe/CNS involvement; azoles for extrathoracic w/o CNS involvement; some cases require debridement</p>
<p class="h">Blastomycosis <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2008;46:1801)</span></p>
<p class="noindent1">• <b class="calibre7">Epidemiology</b> endemic to the eastern ½ of U.S.</p>
<p class="noindent1">• <b class="calibre7">Clinical manifestations</b></p>
<p class="noindent2">Acute: PNA w/o hilar LAN that can progress to ARDS</p>
<p class="noindent2">Chronic: cough + “B” sx, fibronodular infiltrates, masses ± cavitary lesions (Ddx TB, histo)</p>
<p class="noindent2">Disseminated (seen in immunosupp.): rash (verrucous, ulcerated lesions), subcutaneous nodules, osteo, GU (prostatitis, epididymoorchitis), CNS involvement uncommon</p>
<p class="noindent1">• <b class="calibre7">Treatment:</b> mild to mod: itraconazole; disseminated/severe/CNS: ampho → itraconazole</p>
<h2 class="ct"><a id="h86" class="calibre8"></a><a href="part0003.html#rh95" class="calibre8">INFXNS IN IMMUNOSUPPRESSED HOSTS</a></h2>
<p class="h">Overview</p>
<p class="noindent1">• Many Pts have ≥1 risk (eg, DM, ESRD, transplant, extremes of age)</p>
<p class="noindent1">• Accurate dx of opportunistic infections and targeted Rx key in this population</p>
<p class="noindent1">• The following is not an exhaustive list, but a delineation of common or classic etiologies</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Predisposition</b></p></td>
<td class="th"><p class="tbodyh"><b class="calibre7">Classic Infectious Etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Humoral immune dysfunction</b> (eg, CVID, myeloma) and <b class="calibre7">asplenia</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Encapsulated bacteria:</b> <i class="calibre6">S. pneumo</i>, <i class="calibre6">H. flu</i>, <i class="calibre6">N. meningitidis</i> (vaccinate against these 3, ideally prior to splenectomy)</p>
<p class="tbodyh"><b class="calibre7">Other bacteria:</b> <i class="calibre6">E. coli</i> and other GNRs, <i class="calibre6">Capnocytophaga</i></p>
<p class="tbodyh"><b class="calibre7">Parasites:</b> <i class="calibre6">Babesia, Giardia;</i> <b class="calibre7">Viruses:</b> VZV, echovirus, enterovirus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Granulocytopenia or neutropenia</b> (includes DM, ESRD → functional impairment)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Bacteria:</b> <span class="underline">Gram positive</span>: coag ⊖ staph, <i class="calibre6">S. aureus</i>, viridans strep, <i class="calibre6">S. pneumo</i>, other strep; <i class="calibre6">Corynebacterium</i> spp., <i class="calibre6">Bacillus</i> spp. <span class="underline">Gram negative</span>: <i class="calibre6">E. coli</i>, <i class="calibre6">Klebsiella</i>, <i class="calibre6">Pseudomonas</i></p>
<p class="tbodyh"><b class="calibre7">Fungi:</b> Yeast: <i class="calibre6">Candida albicans</i> and other <i class="calibre6">Candida</i> spp. <span class="underline">Molds</span>: <i class="calibre6">Aspergillus, Mucor</i> spp., endemic fungi and others</p>
<p class="tbodyh"><b class="calibre7">Viruses:</b> VZV, HSV1 and 2, CMV</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Impaired cell-mediated immunity (CMI)</b> (eg, HIV/AIDS, chronic steroids, posttransplant, DM, ESRD, autoimmune dis.)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Bacteria:</b> <i class="calibre6">Salmonella spp., Campylobacter, Listeria, Yersinia, Legionella</i> <span class="sm">(<i class="calibre6">Lancet</i> 2016;387:376)</span><i class="calibre6">, Rhodococcus, Nocardia,</i> TB, non-TB mycobacteria</p>
<p class="tbodyh"><b class="calibre7">Fungi:</b> <i class="calibre6">Candida, Crypto, Histo, Coccidio, Aspergillus, Pneumocystis, Zygomycetes</i> spp. and other molds</p>
<p class="tbodyh"><b class="calibre7">Viruses:</b> HSV, VZV, CMV, EBV, JC virus, BK virus</p>
<p class="tbodyh"><b class="calibre7">Parasites:</b> <i class="calibre6">Toxoplasma, Cryptosporidium, Isospora, Microsporidia Babesia; Strongyloides</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Organ dysfunction</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Liver (esp. cirrhosis):</b> <i class="calibre6">Vibrio</i> spp., encapsulated bacteria</p>
<p class="tbodyh"><b class="calibre7">ESRD:</b> impaired granulocyte fxn and CMI as above</p>
<p class="tbodyh">Iron overload (or deferoxamine Rx): <i class="calibre6">Yersinia</i>, <i class="calibre6">Zygomycetes</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Biologics</b> (eg, TNF inhibitors, anti-B- cell Rx; ✓ for TB before starting)</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Bacteria:</b> sepsis, septic arthritis, TB, NTM, <i class="calibre6">Listeria</i>, <i class="calibre6">Legionella</i></p>
<p class="tbodyh"><b class="calibre7">Fungi:</b> <i class="calibre6">Pneumocystis, Histo, Coccidio, Aspergillus</i>, endemic fungi</p>
<p class="tbodyh"><b class="calibre7">Viruses:</b> JC virus (PML), EBV, HSV, VZV, HBV</p>
<p class="tbodyh"><b class="calibre7">Parasites:</b> <i class="calibre6">Strongyloides</i> reactivation</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">NEJM</i> 2007;357:2601; <i class="calibre6">Am J Med</i> 2007;120:764; <i class="calibre6">CID</i> 2011;53:798)</p>
<h2 class="ct"><a id="h87" class="calibre8"></a><a id="page_6-5" class="calibre8"></a><a href="part0003.html#rh96" class="calibre8">URINARY TRACT INFECTIONS</a></h2>
<p class="h">Definitions</p>
<p class="noindent1">• <b class="calibre7">Asymptomatic bacteriuria:</b> presence of bacteria in urine without signs or sx of infection</p>
<p class="noindent1">• <b class="calibre7">Uncomplicated:</b> confined to bladder. No upper tract or systemic infection signs.</p>
<p class="noindent1">• <b class="calibre7">Complicated:</b> extends beyond bladder (pyelonephritis, renal/perinephric abscess, prostatitis) with symptoms of fever, rigors, malaise, flank pain, CVA tenderness or pelvic/perineal pain. More likely to develop bacteremia or sepsis. Men, those w/ nephrolithiasis, strictures, stents, urinary diversions, immunosupp, DM, are not automatically complicated. Pregnant &amp; renal Tx <i class="calibre6">are</i> considered complicated.</p>
<p class="h">Microbiology</p>
<p class="noindent1">• Uncomplicated: <b class="calibre7"><i class="calibre6">E. coli</i></b> (80%), <i class="calibre6">Proteus</i>, <i class="calibre6">Klebsiella</i>, <i class="calibre6">S. saprophyticus</i> <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2004;39:75)</span>. In healthy, nonpregnant women, lactobacilli, enterococci, Group B strep, and coag-neg staph (except <i class="calibre6">S. saprophyticus</i>) are likely <i class="calibre6">contaminants</i> <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2012;156:ITC3)</span>.</p>
<p class="noindent1">• Complicated: as above + PsA, enterococci, staph (uncommon 1º urinary pathogen w/o catheter or recent instrumentation; ? bacteremia w/ hematogenous spread). ↑ MDR.</p>
<p class="noindent1">• Catheter-associated: <i class="calibre6">E. coli</i> most prevalent, candida, <i class="calibre6">Enterococcus,</i> PsA, other GNR</p>
<p class="noindent1">• Urethritis: <i class="calibre6">Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum, Trichomonas vaginalis, Mycoplasma genitalium</i>, HSV</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Cystitis: dysuria</b>, <b class="calibre7">urgency</b>, <b class="calibre7">frequency</b>, hematuria, suprapubic pain; fever <i class="calibre6">absent.</i> R/o vaginitis if symptoms of cystitis &amp; urethritis. Neurogenic bladder Pts may have atypical sx (↑ spasticity, autonomic dysreflexia, malaise).</p>
<p class="noindent1">• <b class="calibre7">Urethritis:</b> dysuria, urethral discharge (see “STI”)</p>
<p class="noindent1">• <b class="calibre7">Prostatitis</b></p>
<p class="noindent2">Chronic: similar to cystitis + <i class="calibre6">symptoms of obstruction</i> (hesitancy, weak stream)</p>
<p class="noindent2">Acute: perineal pain, fever, tenderness on prostate exam</p>
<p class="noindent1">• <b class="calibre7">Pyelonephritis:</b> fever, chills, flank or back pain, nausea, vomiting, diarrhea</p>
<p class="noindent1">• <b class="calibre7">Renal abscess</b>: pyelonephritis sx + <i class="calibre6">persistent fever on appropriate antibiotics</i></p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:562)</span></p>
<p class="noindent1">• <b class="calibre7">Urinalysis: pyuria</b> + bacteriuria ± hematuria ± nitrites</p>
<p class="noindent1">• <b class="calibre7">Urine Cx</b> (clean-catch midstream or straight-cath)</p>
<p class="noindent2">Obtain cx only if symptoms (although in ill Pts, can include ∆MS, autonomic instability)</p>
<p class="noindent2">⊕ if: ≥10<sup class="calibre19">5</sup> CFU/mL, though &lt;10<sup class="calibre19">5</sup> but<sup class="calibre19"/> ≥10<sup class="calibre19">2</sup>/mL may still indicate UTI in some scenarios</p>
<p class="noindent2">Pyuria &amp; ⊖ UCx=sterile pyuria. Ddx: prior abx, nephrolithiasis, interstitial nephritis, tumor, TB, urethritis (see “STI”)</p>
<p class="noindent1">• <b class="calibre7">Catheter-associated:</b> requires (1) s/s (incl atypical) + (2) urine Cx w/ 1 species ≥10<sup class="calibre19">3</sup> colonies from clean urine sample (<b class="calibre7">after</b> replacing Foley). Pyuria alone <i class="calibre6">not</i> sufficient to dx</p>
<p class="noindent1">• Blood cultures: obtain in febrile Pts; consider in complicated UTIs</p>
<p class="noindent1">• For all men w/ UTI, consider prostatitis: ✓ prostate exam</p>
<p class="noindent1">• CT A/P: consider in severely ill, obstruction, persistent sx after 48–72 hours of approp abx</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment of UTIs</b> <span class="sm">(<i class="calibre6">CID</i> 2011;52:e103; <i class="calibre6">JAMA</i> 2014;312:1677)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Scenario</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Empiric Treatment Guidelines</b> (narrow based on UCx)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Asymptomatic bacteruria</b></p></td>
<td class="th1"><p class="tbodyh">Do <i class="calibre6">not</i> treat. Exceptions: pregnant women, renal transplant, prophylaxis prior to invasive urologic procedures <span class="sm">(<i class="calibre6">CID</i> 2019;68:1611)</span><i class="calibre6">.</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cystitis</b> <span class="sm">(<i class="calibre6">JAMA</i> 2014;16:1677)</span></p></td>
<td class="th1"><p class="tbodyh">Uncomp: nitrofurantoin (Macrobid 100 mg PO q12h or Macrodantin 100 mg PO q6h) × 5 d <i class="calibre6">or</i> TMP-SMX DS × 3 d <i class="calibre6">or</i> fosfomycin (3 g × 1). Refer to dosing guidelines for ↑ Cr.</p>
<p class="tbodyh">Complicated: outPt FQ or TMP-SMX PO × 7–14 d</p>
<p class="tbodyh">FQ or TMP-SMX superior to β-lactams <span class="sm">(<i class="calibre6">NEJM</i> 2012;366:1028)</span></p>
<p class="tbodyh">InPt: CTX or FQ; PO if improving, if growing GPC add vancomycin</p>
<p class="tbodyh">If catheterized <b class="calibre7">remove or exchange catheter</b>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Prostatitis</b></p></td>
<td class="th1"><p class="tbodyh">FQ or TMP-SMX PO × 14–28 d (acute) or 6–12 wk (chronic)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pyelonephritis</b></p></td>
<td class="th1"><p class="tbodyh">OutPt: FQ × 7 d <i class="calibre6">or</i> TMP-SMX PO × 14 d <span class="sm">(<i class="calibre6">Lancet</i> 2012;380:452)</span></p>
<p class="tbodyh">InPt: CTX × 14 d; if at risk for MDR pathogen cefepime, pip-tazo, carbapenem, or plazomicin <span class="sm">(<i class="calibre6">NEJM</i> 2019;380:729)</span> (Δ IV → PO when clinically improved &amp; afebrile 24–48 h, tailor to Cx)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Renal abscess</b></p></td>
<td class="th1"><p class="tbodyh">Drainage + antibiotics as for pyelonephritis</p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h88" class="calibre8"></a><a id="page_6-6" class="calibre8"></a><a href="part0003.html#rh97" class="calibre8">SEXUALLY TRANSMITTED INFECTIONS</a></h2>
<p class="h">Risk Factors and Screening <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2021;70:1)</span></p>
<p class="noindent1">• <b class="calibre7">High risk:</b> &gt;10 lifetime sexual partners, prior STI, MSM, sex workers</p>
<p class="noindent1">• Screening recommendations: differ based on sexual practices and risk. All adults should have one-time HIV Ag/Ab, HCV Ab. Consider q3mo testing for STIs if high risk.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre12"/>
<col class="calibre13"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Genital Lesions</b> <span class="sm">(<i class="calibre6">MMWR</i> 2021; 70:1)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Disease</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Symptoms</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1" rowspan="3"><p class="tbodyc">Painless</p></td>
<td class="th1"><p class="tbodyc">Syphilis</p>
<p class="tbodyc"><i class="calibre6">(T. pallidum)</i></p></td>
<td class="th1"><p class="tbodyh">1°: <b class="calibre7">chancre</b> = firm, indurated, clean base</p>
<p class="tbodyh">2°: fever, LAN, rash palms/soles, uveitis, condylomata lata</p>
<p class="tbodyh">3°: aortitis/aneurysm, gumma, CN palsies (7/8), tabes dorsalis, aseptic meningitis</p>
<p class="tbodyh"><span class="underline">Latent</span> = asx; <span class="underline">early latent</span> &lt;1yr; <span class="underline">late</span> &gt;1yr/unknown</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">LGV</p>
<p class="tbodyc">(<i class="calibre6">C. trachomatis, L</i>1<i class="calibre6">–L3</i>)</p></td>
<td class="th1"><p class="tbodyh">1°: transient papule</p>
<p class="tbodyh">2°: 2–6 wks later, painful inguinal LN (buboes)</p>
<p class="tbodyh">3°: Anorectal syndrome w/ proctitis, ulcers</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Donovanosis/GI (<i class="calibre6">K. granulomatis</i>)</p></td>
<td class="th1"><p class="tbodyh">Multiple beefy, firm, irregular ulcers (“granuloma inguinale”), no LAN; in tropics</p></td>
</tr>
<tr class="calibre15">
<td class="th1" rowspan="2"><p class="tbodyc">Painful</p></td>
<td class="th1"><p class="tbodyc">Genital herpes</p>
<p class="tbodyc">(HSV 2&gt;1)</p></td>
<td class="th1"><p class="tbodyh">Prodrome: multiple painful vesicles</p>
<p class="tbodyh">1° outbreak: more severe ± LAN/fever</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Chancroid (<i class="calibre6">H. ducreyi</i>)</p></td>
<td class="th1"><p class="tbodyh">Multiple ulcers ± LAN, in tropics</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2021;70:1;</span> <span class="r2">JAMA</span><span class="r1"> 2022;327:161)</span></p>
<p class="noindent1">• Syphilis: 1<sup class="calibre19">st</sup> step is treponemal test: IgG to <i class="calibre6">T. pallidum</i>. ⊕ for life.</p>
<p class="noindent2">2<sup class="calibre19">nd</sup> step: confirm w/ non-treponemal test (VDRL/RPR titer). Should ↓ 4-fold w/ Rx.</p>
<p class="noindent2">Neurosyphilis: LP not needed if only ocular or otic sx. CSF VDRL may be ⊖.</p>
<p class="noindent1">• LGV: clinical dx + ⊕ rectal <i class="calibre6">C. trachomatis</i> NAAT + r/o other causes of proctitis</p>
<p class="noindent1">• Donovanosis: bx w/ Donovan bodies (encapsuled GNR) in monocytes/macrophages</p>
<p class="noindent1">• Genital herpes: clinical dx; confirm w/ PCR, viral cx from lesion</p>
<p class="noindent1">• Chancroid: clinical dx; r/o syphilis &amp; HSV</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2021;70:1;</span> <span class="r2">JAMA</span> <span class="r1">2022;327:161)</span></p>
<p class="noindent1">• Syphilis</p>
<p class="noindent2">1°/2°/early latent: PCN G benzathine 2.4 mil U IM × 1</p>
<p class="noindent2">3°/late latent: PCN G 2.4 mil U IM × 3</p>
<p class="noindent2">Neuro: IV PCN G 4 mil U q4h 10–14 d <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2011; 53:S110)</span></p>
<p class="noindent1">• LGV: doxy 100 mg BID × 21 d + aspiration of buboes</p>
<p class="noindent1">• Donovanosis: azithro 1g qwk × 3 wks, until healed <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2015;64)</span></p>
<p class="noindent1">• Genital herpes: valacyclovir 1g bid × 7–10 d. Consider suppression if &gt;6 outbreaks/yr.</p>
<p class="noindent1">• Chancroid: azithro 1g × 1 PO <i class="calibre6">or</i> cipro 500 mg bid × 3 d</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre33"/>
<col class="calibre43"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Genital Discharge</b> <span class="sm">(<i class="calibre6">MMWR</i> 2021;70:1)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Disease</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Symptoms</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Gonorrhea <i class="calibre6">(N. gonorrhoeae)</i></p>
<p class="tbodyc">&amp; Chlamydia (<i class="calibre6">C. trachomatis</i>)</p></td>
<td class="th1"><p class="tbodyh">♀: Mucopurulent cervicitis, dysuria, PID; can be asx</p>
<p class="tbodyh">♂: Urethritis, infxn of epididymis/prostate</p>
<p class="tbodyh">All: pharyngitis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><i class="calibre6">Mycoplasma genitalium</i></p></td>
<td class="th1"><p class="tbodyh">Suspect in Pts w/ urethritis/cervicitis after Rx for GC/CT</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Trichomoniasis (<i class="calibre6">T. vaginalis</i>)</p></td>
<td class="th1"><p class="tbodyh">♀: Malodorous purulent discharge, dysuria, dyspareunia</p>
<p class="tbodyh">♂: Asymptomatic</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Bacterial vaginosis (<i class="calibre6">Gardnerella vaginalis</i>)</p></td>
<td class="th1"><p class="tbodyh">♀: Malodorous grey/white discharge, no dyspareunia</p></td>
</tr>
</tbody>
</table>
<p class="tfn">♀ denotes all persons with a vagina. ♂ denotes all persons with a penis.</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2021;70:1;</span> <span class="r2">JAMA</span><span class="r1"> 2022;327:161)</span></p>
<p class="noindent1">• NAAT (vaginal/cervical/urine ♀; urine ♂), mycoplasma testing not widely available</p>
<p class="noindent1">• For GC/CT, strongly suggest urine + rectal/pharyngeal swab if history of oral or anal sex</p>
<p class="noindent1">• Trichomoniasis: motile trichomonads on wet mount</p>
<p class="noindent1">• Bacterial vaginosis: clue cells on wet mount; ⊕ whiff test; vaginal culture</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">MMWR</span><span class="r1"> 2021;70:1;</span> <span class="r2">JAMA</span><span class="r1"> 2022;327:161)</span></p>
<p class="noindent1">• GC: CTX 500 mg IM × 1 (if wt &gt;150 kg, 1 g). CT: doxy 100 mg PO bid × 7 d (preferred) or azithro 1 g PO × 1. Do <i class="calibre6">not</i> need to treat both if neg NAAT. Retest at 3 mos.</p>
<p class="noindent1">• <i class="calibre6">M. gen.</i>: doxy 100 mg PO bid × 7 d, then: moxifloxacin 400 mg PO qd × 7 d</p>
<p class="noindent1">• Trich: ♀ → MNZ 500 mg PO bid <i class="calibre6">or</i> tinidazole 2 g PO qd × 7 d. ♂ → MNZ 2 g PO × 1.</p>
<p class="noindent1">• Bacterial vaginosis: MNZ 500 mg PO bid × 7 d <i class="calibre6">or</i> vaginal Rx w/ MNZ gel daily × 5 d</p>
<h2 class="ct"><a id="h89" class="calibre8"></a><a id="page_6-7" class="calibre8"></a><a href="part0003.html#rh98" class="calibre8">SKIN AND SOFT TISSUE INFECTIONS</a></h2>
<p class="h">Definitions</p>
<p class="noindent1">• <b class="calibre7">Cellulitis:</b> infection of dermis and subcutaneous tissue characterized by erythema, warmth, tenderness, and swelling; often occurs as a result of skin breaches <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:3)</span></p>
<p class="noindent1">• <b class="calibre7">Skin abscess:</b> subcutaneous collection of pus</p>
<p class="noindent1">• Staph toxic shock syndrome: rapid onset fever, rash, hypotension, and multiorgan injury. <i class="calibre6">Staph aureus</i> cx are not necessary for dx. Often associated with packing (tampon, nasal packing). Management may require surgical debridement + abx.</p>
<p class="h">Risk Factors</p>
<p class="noindent1">• Trauma, edema, preceding skin inflammation or infection, obesity, DM, other immunosupp.</p>
<p class="h">Microbiology <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2014;59:e10)</span></p>
<p class="noindent1">• Purulent: <b class="calibre7">MRSA</b> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;355:666)</span> causes up to 75% of purulent skin/soft tissue infections, followed by MSSA and strep</p>
<p class="noindent1">• Non-purulent: <i class="calibre6">Strep</i>, MSSA, aerobic GNRs. MRSA less commonly unless significant risk factors (prior MRSA infection, IVDU, HD, recent abx or hospitalization).</p>
<p class="noindent1">• Bites: <b class="calibre7">skin</b> (<b class="calibre7"><i class="calibre6">Strep</i>, <i class="calibre6">Staph</i></b> [MRSA only if risk factors]) and <b class="calibre7">oral flora</b> (including anaerobes) + special exposures:</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre12"/>
<col class="calibre18"/>
<col class="calibre23"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Feature</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Microbiology</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Clinical</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cat bite<sup class="calibre27"><a id="fn137-s1" class="calibre8"></a><a href="part0012.html#rfn137-s1" class="calibre8">*</a></sup></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Pasturella spp</i></p></td>
<td class="th1"><p class="tbody">Rapid onset erythema, swelling, lymphangitis, fever</p></td>
<td class="th1"><p class="tbody">Amox/clav</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Dog bite</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Pasturella &amp; Capnocytophaga spp</i></p></td>
<td class="th1"><p class="tbody">Can cause severe sepsis w/ DIC &amp; gangrene in asplenic/cirrhotics and other immunosupp.</p></td>
<td class="th1"><p class="tbody">Amox/clav</p>
<p class="tbody">If Capno. suspected: pip/tazo or carbapenem</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Penetrating injury</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Pseudomonas</i></p></td>
<td class="th1"><p class="tbody">Can be a/w deep tissue abscess</p></td>
<td class="th1"><p class="tbody">Directed based on suscept.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Gardening</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Sporothrix</i></p></td>
<td class="th1"><p class="tbody">Ulcerating nodules, lymphatic spread</p></td>
<td class="th1"><p class="tbody">Itraconazole</p></td>
</tr>
<tr class="calibre15">
<td rowspan="2" class="th1"><p class="tbody">Salt H<sub class="calibre17">2</sub>O or raw oysters/fish</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">V. vulnificus</i></p></td>
<td class="th1"><p class="tbody">Hemorrhagic bullae &amp; sepsis (esp. in cirrhotics)</p></td>
<td class="th1"><p class="tbody">Doxy + Ceftaz/CTX</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Mycobacterium marinum</i></p></td>
<td class="th1"><p class="tbody">Indolent, nodules on extremities/ superficial lymphadenitis</p></td>
<td class="th1"><p class="tbody">Macrolide + rifampin/ ethambutol</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fresh H<sub class="calibre17">2</sub>O</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Aeromonas</i></p></td>
<td class="th1"><p class="tbody">Myonecrosis/rhabdo can occur.</p></td>
<td class="th1"><p class="tbody">FQ, TMP-SMX, or CTX</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn137-s1" class="calibre8"></a><a href="part0012.html#fn137-s1" class="calibre8">*</a></sup>Cat scratch disease caused by <i class="calibre6">Bartonella</i> acquired via cat scratch or bite. Results in lymphadenitis.</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Clinical diagnosis based on physical examination</p>
<p class="noindent1">• Cultures from intact skin are not helpful and should <i class="calibre6">not</i> be performed <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2014;59:e10)</span></p>
<p class="noindent1">• BCx are typically low yield (~5–10%)</p>
<p class="noindent1">• Ultrasound can be used to identify deep abscesses and facilitate drainage. If abscess is found, incision/drainage is key to treatment.</p>
<p class="noindent1">• Aspirate from an abscess may provide microbiologic dx</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre12"/>
<col class="calibre25"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td colspan="4" class="th"><p class="tbody"><b class="calibre7">Cellulitis Treatment</b> <span class="sm">(<i class="calibre6">NEJM</i> 2014;370:2238; <i class="calibre6">CID</i> 2014;59:e10; <i class="calibre6">JAMA</i> 2016;316:325 &amp; 2017;317:2088)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Purulent</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Usual Micro</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Severity</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Treatment</b></p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbodyc">No</p></td>
<td class="tb" rowspan="3"><p class="tbodyc">β-hemolytic <i class="calibre6">Strep</i> &gt;<i class="calibre6">S. aureus</i></p></td>
<td class="th1"><p class="tbodyc">Mild</p></td>
<td class="th1"><p class="tbodyh">Oral: PCN VK, cephalosporin</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Mod</p></td>
<td class="th1"><p class="tbodyh">IV: PCN, ceftriaxone, cefazolin</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Severe</p></td>
<td class="th1"><p class="tbodyh">IV: vanc + pip/tazo (± clinda for toxic shock syndrome)</p></td>
</tr>
<tr class="calibre15">
<td class="tb" rowspan="3"><p class="tbodyc">Yes</p></td>
<td class="tb" rowspan="3"><p class="tbodyc"><i class="calibre6">S. aureus</i> (incl. MRSA) &gt;&gt; β-hemolytic <i class="calibre6">Strep</i></p></td>
<td class="th1"><p class="tbodyc">Mild</p></td>
<td class="th1"><p class="tbodyh">Consider I&amp;D only vs. I&amp;D + clinda or TMP-SMX <span class="sm">(<i class="calibre6">NEJM</i> 2017;376:2545)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Mod</p></td>
<td class="th1"><p class="tbodyh">I&amp;D + TMP-SMX or doxycycline</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Severe</p></td>
<td class="th1"><p class="tbodyh">I&amp;D + IV vanc, daptomycin or linezolid (± clinda for toxic shock syndrome)</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Mild: abscess &lt;2 cm, no systemic signs of infection, immunocompetent, no indwelling hardware; moderate: systemic signs; severe: SIRS or immunosuppressed</p>
<p class="noindent1">• <b class="calibre7">Limb elevation;</b> erythema may <i class="calibre6">worsen</i> after starting abx b/c bacterial killing → inflam.</p>
<p class="noindent1">• In obese Pts, adequate drug dosing important to avoid treatment failure <span class="r1">(</span><span class="r2">J Infect</span> <span class="r1">2012;2:128)</span></p>
<p class="noindent1">• <b class="calibre7">Duration:</b> 5 to up to 14 d based on severity and response to treatment. Take pictures &amp; draw margins to track progress.</p>
<p class="h1cr"><a id="page_6-8" class="calibre8"></a>N<small class="calibre31">ECROTIZING</small> S<small class="calibre31">OFT</small>-T<small class="calibre31">ISSUE</small> I<small class="calibre31">NFECTIONS</small> <span class="r3">(</span><span class="r4">NEJM</span> <span class="r3">2017;377:2253)</span></p>
<p class="h">Definition</p>
<p class="noindent1">• Fulminant tissue destruction, systemic toxicity &amp; high mortality. <b class="calibre7">Surgical emergency</b>.</p>
<p class="noindent1">• May include cellulitis, fasciitis, myositis, myonecrosis (gas gangrene).</p>
<p class="h">Risk factors</p>
<p class="noindent1">• Can affect healthy individuals via skin/mucosal breach or traumatic wound, but ↑ risk w/ DM, PVD, EtOH abuse, IVDU, cirrhosis, or other immunosupp.</p>
<p class="h">Microbiology</p>
<p class="noindent1">• <b class="calibre7">Necrotizing fasciitis</b></p>
<p class="noindent1">• Type I: polymicrobial (mixed aerobes &amp; anaerobes), typically in older Pts w/ above RFs. <b class="calibre7">Fournier’s gangrene</b> involves genitalia and/or perineum</p>
<p class="noindent2">Head and neck NSTI evolve from oral flora including anaerobes</p>
<p class="noindent1">• Type II: monomicrobial, usually group A strep, less likely <i class="calibre6">Staph, Vibrio, Aero.</i>; a/w TSS</p>
<p class="noindent1">• <b class="calibre7">Clostridial myonecrosis (gas gangrene):</b> <i class="calibre6">C. perfringens; C. septicum</i> (large Gram ⊕ rods w/ blunt ends on Gram stain). A/w traumatic wounds that create an anaerobic environment ideal for <i class="calibre6">Clostridia</i>.</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Erythema, edema, warmth + <b class="calibre7">systemic illness</b> ±<b class="calibre7"> crepitus,</b> bullae, necrosis</p>
<p class="noindent1">• <b class="calibre7">Rapid progression</b> of clinical signs</p>
<p class="noindent1">• <b class="calibre7">Pain out of proportion</b> to apparent cellulitis; skin hyperesthetic and later anesthetic</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Clinical dx is sufficient to initiate <b class="calibre7">urgent surgical exploration</b></p>
<p class="noindent1">• Aspiration of necrotic center; BCx; Gram stain; lactate, AST, &amp; CK for deep tissue necrosis</p>
<p class="noindent1">• Imaging: <b class="calibre7">noncontrast CT</b>, but do not delay Rx/surgery <span class="r1">(</span><span class="r2">Arch Surg</span> <span class="r1">2010;145:452)</span></p>
<p class="noindent1">• Microbiologic dx from Gram stain and culture of surgical specimens</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2014;60:169)</span></p>
<p class="noindent1">• Urgent surgical exploration with debridement of necrotic tissue and ID consultation</p>
<p class="noindent1">• Empiric antibiotics: [pip/tazo <i class="calibre6">or</i> ceftriaxone + metronidazole <i class="calibre6">or</i> carbapenem] + [vanco or linezolid]. For Group A Strep: penicillin + clindamycin + consideration of IVIG for toxic shock.</p>
<p class="h1cr">D<small class="calibre31">IABETIC</small> F<small class="calibre31">OOT</small> I<small class="calibre31">NFECTIONS</small></p>
<p class="h">Microbiology and severity <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2004;39:885)</span></p>
<p class="noindent1">• <b class="calibre7">Mild</b> (superficial ulcer, no involvement of deeper structures, surrounding erythema &lt;2 cm, and no systemic illness): usually <i class="calibre6">S. aureus</i> or aerobic streptococci</p>
<p class="noindent1">• <b class="calibre7">Moderate</b> (ulcer with involvement of deeper structures, surrounding erythema &gt;2 cm, or lymphangitic streaking and no systemic illness): more likely to be chronic and polymicrobial (PsA, enterococci, enteric GNR<i class="calibre6">,</i> anaerobes)</p>
<p class="noindent1">• <b class="calibre7">Severe</b> (moderate + systemic illness or metabolic instability): anaerobic streptococci, enteric GNR, PsA, <i class="calibre6">Bacteroides</i>, <i class="calibre6">Clostridium</i></p>
<p class="h">Initial evaluation</p>
<p class="noindent1">• Cleanse, debride, probe, and obtain deep anaerobic + aerobic cultures</p>
<p class="noindent1">• Assess for PVD: sensation, pulses, ABIs</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• <b class="calibre7">Deep tissue wound cx</b> at time of debridement (ideally prior to antibiotics). Superficial swabs are typically of limited utility due to colonization.</p>
<p class="noindent1">• For mod/severe: obtain blood cx, ESR, CRP</p>
<p class="noindent1">• <b class="calibre7">Osteomyelitis should always be ruled out.</b> At ↑ risk if: grossly visible bone or able to probe to bone, ulcer &gt;2 cm, ulcer duration &gt;1–2 wk, ESR &gt;70. If suspicious for osteo, obtain plain films ± MRI (see osteomyelitis below).</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2012;54:e132)</span></p>
<p class="noindent1">• <b class="calibre7">Mild infxn:</b> oral abx. Target GPCs (diclox, cephalexin, or amox/clav); use TMP-SMX or doxy for MRSA.</p>
<p class="noindent1">• <b class="calibre7">Mod/severe infxn:</b> IV abx. Target GPCs (vanco, linezolid,dapto) + GNRs (CTX, levo, or amp/sulb) ± anaerobes (metronidazole or clinda). Add PsA coverage (cefepime or pip- tazo) if: macerated wound, significant water exposure, warm climate</p>
<p class="noindent1">• Elevation, non–weight-bearing status, wound care, glycemic control, Rx for venous insufficiency and arterial ischemia</p>
<p class="noindent1">• <b class="calibre7">Many require surgery:</b> early, aggressive, and repeated debridement; revascularization or amputation may be necessary</p>
<p class="h1cr"><a id="page_6-9" class="calibre8"></a>O<small class="calibre31">STEOMYELITIS</small></p>
<p class="center"><i class="calibre6">Infection of bone due to hematogenous seeding or direct spread from contiguous focus</i></p>
<p class="h">Etiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2004;364:369)</span></p>
<p class="noindent1">• <b class="calibre7">Hematogenous: <i class="calibre6">S. aureus</i></b>; mycobacterial infection of vertebral body = Pott’s disease</p>
<p class="noindent1">• <b class="calibre7">Contiguous focus</b> (may be acute or chronic)</p>
<p class="noindent2">Open fracture, orthopedic surgery, etc.: <b class="calibre7"><i class="calibre6">S. aureus</i></b> and <b class="calibre7"><i class="calibre6">S. epi</i></b></p>
<p class="noindent2">Skin breakdown + vasc. insuffic. (eg, diabetic foot, pressure ulcer): <b class="calibre7">polymicrobial</b></p>
<p class="noindent2">GU source (GNR, <i class="calibre6">Enterococcus</i>)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Surrounding soft-tissue compromise ± fistula to superficial skin</p>
<p class="noindent1">• ± Fever, malaise, and night sweats (more common in hematogenous than contiguous)</p>
<p class="noindent1">• Vertebral osteomyelitis (esp. IVDU): unremitting, focal back pain, ± fever <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;362:1022)</span></p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2008;299:806)</span></p>
<p class="noindent1">• Crucial to obtain cx data of causative organism to avoid long-term empiric abx</p>
<p class="noindent1">• <b class="calibre7">Bone biopsy</b> or <b class="calibre7">tissue cx</b> obtained surgically or via percutaneous biopsy (send aerobic, anaerobic, mycobacterial, and fungal cultures + pathology) unless ⊕ blood cx. Do not rely on swabs of ulcers or fistulae drainage.</p>
<p class="noindent1">• Physical exam: high suspicion in diabetic foot (see above) if can probe ulcer to bone or ulcer &gt;2 cm<sup class="calibre19">2</sup> (Sp 83%, 90% PPV)</p>
<p class="noindent1">• <b class="calibre7">Blood cultures before antibiotics</b> (more often ⊕ w/ acute hematogenous osteomyelitis)</p>
<p class="noindent1">• CBC, CRP, ESR (&gt;70 greatly ↑ likelihood of osteo)</p>
<p class="noindent1">• Imaging</p>
<p class="noindent2">Plain radiographs: normal early in disease; lytic lesions seen after 2–6 wk</p>
<p class="noindent2"><b class="calibre7">MRI:</b> preferred imaging study (overall Se 90%, Sp 82%; <span class="r2">Archives</span><span class="r1"> 2007;167:125</span>)</p>
<p class="noindent2">CT: can demonstrate periosteal reaction and cortical and medullary destruction</p>
<p class="noindent2">CT &amp; MRI very Se but ↓ Sp; false ⊕ if contig focus w/ periosteal reaction, Charcot Δs</p>
<p class="noindent2">Radionuclide imaging: very Se but non-Sp (false ⊕ if soft-tissue inflammation)</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Antibiotics:</b> based on cx data. If clinically stable, consider holding antibiotics until bone bx obtained. Duration depends on Rx strategy/goals of Rx management (eg, 6 wks for vertebral osteo; <span class="r2">Lancet</span><span class="r1"> 2015;385:875</span>). After ≥7 days from either start of IV abx or surgery, if doing well consider (in consultation with ID!) ∆’ing IV to PO (if good bioavailability and bone penetration) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:425)</span>.</p>
<p class="noindent1">• <b class="calibre7">Surgery</b> should be considered for any of the following: acute osteo that fails to respond to medical Rx, chronic osteo, complications of pyogenic vertebral osteo (eg, neurologic compromise, spinal instability, epidural abscess) or infected prosthesis</p>
<p class="h1cr">E<small class="calibre31">PIDURAL</small> A<small class="calibre31">BSCESS</small></p>
<p class="h">Etiology</p>
<p class="noindent1">• Hematogenous spread (⅔): skin infection, soft tissue (dental abscess), or endocarditis</p>
<p class="noindent1">• Direct extension (⅓): vertebral osteo, sacral ulcer, spinal anesthesia or surgery, LP</p>
<p class="noindent1">• Risk factors: IVDU diabetes, renal failure, alcoholism, immunosuppression</p>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">S. aureus</i></b> most common pathogen; in immunosuppressed, consider fungal, TB, and <i class="calibre6">Nocardia</i></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Back pain</b> with spinal or paraspinal tenderness + <b class="calibre7">fever</b> ± followed by radiculopathy. <i class="calibre6">Sx of cord compression or cauda equina is a surgical emergency.</i></p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• <b class="calibre7">MRI</b> with contrast</p>
<p class="noindent1">• Aspiration of abscess fluid for Gram stain &amp; cx or operative Gram stain &amp; cx</p>
<p class="noindent1">• Blood cx (frequently ⊖)</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Antibiotics</b> (typically MRSA and gram-negative coverage initially then narrowed based on culture data) ±<b class="calibre7"> surgery</b> (decompressive laminectomy and debridement) for failure to improve on medical Rx. Emergent surgery for early s/s of cord compression (w/ vertebral osteo and epidural abscess).</p>
<h2 class="ct"><a id="h90" class="calibre8"></a><a id="page_6-10" class="calibre8"></a><a href="part0003.html#rh99" class="calibre8">INFECTIONS OF THE NERVOUS SYSTEM</a></h2>
<p class="h1cr">A<small class="calibre31">CUTE</small> B<small class="calibre31">ACTERIAL</small> M<small class="calibre31">ENINGITIS</small></p>
<p class="h">Definition</p>
<p class="noindent1">• Inflammation of tissue around the brain/spinal cord</p>
<p class="noindent1">• Usually arising from nasopharynx (hematogenous spread), bacteremia, or direct inoculation (surgery, contiguous infection, trauma, foreign body [eg, CSF shunt])</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Microbiology in Bacterial Meningitis</b> <span class="sm">(<i class="calibre6">NEJM</i> 2011;364:2016)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">S. pneumoniae</i> (30–60%)</p></td>
<td class="th1"><p class="tbodyh">Look for preceding infection (bacteremia, pneumonia, endocarditis)</p>
<p class="tbodyh">Drug-resistant <i class="calibre6">S. pneumoniae:</i></p>
<p class="tbodyh1">~40% PCN-resistant (even <i class="calibre6">intermediate</i> resistance problematic)</p>
<p class="tbodyh1">~&lt;10% 3<sup class="calibre27">rd</sup>-gen. cephalosporin-resistant</p>
<p class="tbodyh">See “Pneumonia” for <i class="calibre6">S. pneumoniae</i> vaccination recs</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">N. meningitidis</i> (10–35%)</p></td>
<td class="th1"><p class="tbodyh">Primarily in age &lt;30 y; associated petechiae or purpura</p>
<p class="tbodyh">↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated</p>
<p class="tbodyh">Vaccine rec for all age 11–18 y, HIV infection, asplenia, C5-9 deficiency</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">H. influenzae</i> (&lt;5%)</p></td>
<td class="th1"><p class="tbodyh">↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated, CSF leak, trauma/surgery, mastoiditis</p>
<p class="tbodyh">Vaccine rec for all children; markedly ↓ incidence</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">L. monocytogenes</i> (5–10%)</p></td>
<td class="th1"><p class="tbodyh">↑ in immunosupp (glucocorticoids, transplant), elderly, malignancy, pregnant, cirrhosis. Outbreaks a/w contaminated dairy &amp; raw veg.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">GNRs (1–10%)</p></td>
<td class="th1"><p class="tbodyh">More common in health care associated meningitis (<i class="calibre6">E. coli, Klebsiella sp., Pseudomonas aeruginosa)</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Staphylococci</i> (5%)</p></td>
<td class="th1"><p class="tbodyh">Preceding infection (endocarditis, bacteremia), post CNS surgery, foreign bodies (CSF shunt, intrathecal pump)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Mixed infection</p></td>
<td class="th1"><p class="tbodyh">Suspect parameningeal focus or CSF leak, post CNS surgery</p></td>
</tr>
</tbody>
</table>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;339:16)</span></p>
<p class="noindent1">• Headache (84%), fever (74%), stiff neck (74%), photosensitivity, GCS &lt;14 (71%), nausea (62%), seizure (23%); <b class="calibre7">95% have 2 of 4: HA, fever, stiff neck, ΔMS</b></p>
<p class="noindent1">• Presentation may be <i class="calibre6">atypical</i> (eg, lethargy w/o fever) in elderly and immunosupp.</p>
<p class="h">Physical exam <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2002;35:46;</span> <span class="r2">Am J Emerg Med</span> <span class="r1">2013;31:1601)</span></p>
<p class="noindent1">• Nuchal rigidity (Se 30%, Sp 68%), Kernig’s sign (Se 5%, Sp 95%), Brudzinski’s sign (Se 5%, Sp 95%), jolt sign (HA worsens w/ horizontal rotation) (Se 64%, Sp 43%)</p>
<p class="noindent1">• ± Focal neuro findings (~30%; hemiparesis, aphasia, visual field cuts, CN palsies)</p>
<p class="noindent1">• ± HEENT findings: sinus tenderness, clear rhinorrhea (CSF leak)</p>
<p class="noindent1">• ± Skin and joint findings: petechial rash (<i class="calibre6">N. meningitidis</i>), genital or oral ulcers (HSV), arthritis with joint effusion (<i class="calibre6">N. meningitidis</i>)</p>
<p class="h">Sequential management of bacterial meningitis</p>
<p class="noindent1">1. <b class="calibre7">Blood cx</b>, initiate <b class="calibre7">empiric antibiotics</b>, consider corticosteroids (vide infra)</p>
<p class="noindent1">2. <b class="calibre7">CT head</b> if indicated (see below)</p>
<p class="noindent1">3. <b class="calibre7">LP</b> ASAP (if not contraindicated); yield of CSF cx unlikely to be changed if obtained w/in ~4 h of initiation of abx</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;388:3036)</span></p>
<p class="noindent1">• <b class="calibre7">Blood cultures</b> ×2 <i class="calibre6">before abx</i></p>
<p class="noindent1">• WBC count: &gt;10,000 in &gt;90% of bacterial meningitis in healthy hosts</p>
<p class="noindent1">• Head CT to r/o mass effect before LP <i class="calibre6">if</i> ≥<i class="calibre6">1 high-risk feature:</i> immunosupp., h/o CNS disease, new-onset seizure, focal neuro findings, papilledema, GCS &lt;15 <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2004;39:1267)</span></p>
<p class="noindent1">• <b class="calibre7">Lumbar puncture</b> with opening pressure <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;355:e12)</span></p>
<p class="noindent2">Send CSF for cell count and differential, glucose, protein, Gram stain, bacterial cx</p>
<p class="noindent2">Additional CSF studies based on clinical suspicion: AFB smear/cx (or MTb PCR), cryptococcal Ag, fungal cx, VDRL, PCR (HSV, VZV, enteroviral), cytology</p>
<p class="noindent2">CSF Gram stain has 30–90% Se; cx 80–90% Se if LP done prior to abx though abx should not be delayed for LP if there is concern for bacterial meningitis</p>
<p class="noindent2"><i class="calibre6">Rule of 2s:</i> CSF WBC &gt;2k, gluc &lt;20, TP &gt;200 has &gt;98% Sp for bacterial meningitis</p>
<p class="noindent2">Repeat LP only if no clinical response after 48 h of appropriate abx or CSF shunt</p>
<p class="noindent2">Metagenomic next-generation sequencing ↑ dx yield <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2327)</span></p>
<p class="imaget"><a id="page_6-11" class="calibre4"></a><img src="../images/00088.jpeg" alt="" class="calibre5"/></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Empiric Treatment of Bacterial Meningitis</b> <span class="sm">(<i class="calibre6">Lancet</i> 2012;380:1693)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Adults</b> &lt;<b class="calibre7">50 y</b></p></td>
<td class="th1"><p class="tbody">Ceftriaxone + vancomycin (trough 15–20), consider acyclovir IV</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Adults</b> &gt;<b class="calibre7">50 y</b></p></td>
<td class="th1"><p class="tbody">Ceftriaxone + vancomycin + ampicillin, consider acyclovir IV</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Immunosuppressed</b></p></td>
<td class="th1"><p class="tbody">[Cefepime <i class="calibre6">or</i> meropenem] + vanc ± amp (not nec. if on meropenem), consider acyclovir IV &amp; fungal coverage</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Healthcare assoc. infection (eg, surgery, CSF shunt)</b></p></td>
<td class="th1"><p class="tbody">[Cefepime <i class="calibre6">or</i> meropenem <i class="calibre6">or</i> ceftazidime] + vancomycin</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody">When possible, organism-directed Rx, guided by sensitivities or local patterns of drug resistance should be used</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody">Confirm appropriate dosing as <i class="calibre6">higher doses are often needed in meningitis</i> (though may need to be adjusted for renal function)</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Corticosteroids:</b> If causative organism is unknown, dexamethasone 10 mg IV q6h × 4 d recommended prior to or with initiation of abx. Greatest benefit in <i class="calibre6">S. pneumoniae</i> and GCS 8-11 (↓ neuro disability &amp; mortality by ~50%). Avoid in crypto <span class="sm">(<i class="calibre6">NEJM</i> 2016;374:542)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Prophylaxis:</b> for close contacts of Pt w/ <i class="calibre6">N. meningitidis</i>; rifampin (600 mg PO bid × 2 d) or ciprofloxacin (500 mg PO × 1) or ceftriaxone (250 mg IM × 1).</p>
<p class="tbody">See Microbiology in Bacterial Meningitis Table for available vaccinations.</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Precautions:</b> droplet precautions until <i class="calibre6">N. meningitidis</i> is ruled out</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">A<small class="calibre31">SEPTIC</small> M<small class="calibre31">ENINGITIS</small></p>
<p class="h">Definition</p>
<p class="noindent1">• Clinical/lab evidence of meningeal inflammation with negative bacterial cx (CSF &amp; blood)</p>
<p class="h">Etiologies <span class="r1">(</span><span class="r2">Neurology</span> <span class="r1">2006;66:75)</span></p>
<p class="noindent1">• <b class="calibre7">Viral</b>: enteroviruses are most common cause (summer/fall; rash, GI, URI sx), HIV, HSV, VZV, mumps (parotitis), lymphocytic choriomeningitis virus (rodent exposure), encephalitis viruses, adenovirus, polio, CMV, EBV, WNV</p>
<p class="noindent1">• <b class="calibre7">Focal bacterial infection</b>: brain/epidural/subdural abscess, CNS septic thrombophlebitis</p>
<p class="noindent1">• <b class="calibre7">Partially treated bacterial meningitis</b></p>
<p class="noindent1">• <b class="calibre7">Other infectious</b>: TB, fungal (cryptococcus, coccidiodes), Lyme, syphilis, leptospirosis</p>
<p class="noindent1">• <b class="calibre7">Neoplasm</b>: intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis</p>
<p class="noindent1">• <b class="calibre7">Drug-induced</b> meningitis: NSAIDs, IVIG, antibiotics (TMP-SMX, PCN), anti-epileptics</p>
<p class="noindent1">• <b class="calibre7">Systemic autoimmune illness</b>: SLE, sarcoidosis, Behçet’s, Sjögren’s syndrome, RA</p>
<p class="noindent1">• Mollaret’s: recurrent lymphocytic meningitis, spontaneously resolving (often HSV-2)</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Obtain LP for CSF analysis: lymphocytic pleocytosis common in viral etiologies (see Typical CSF Findings in Meningitis table above)</p>
<p class="noindent1">• Consider CSF cytology and MRI brain/spine to evaluate for malignancy</p>
<p class="noindent1">• Consider serum autoimmune and serum viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric treatment</p>
<p class="h">Empiric treatment</p>
<p class="noindent1">• Suspected bacterial meningitis: see empiric treatment of bacterial meningitis above</p>
<p class="noindent1">• Suspected viral meningitis: if concern for HSV meningoencephalitis → IV acyclovir</p>
<p class="noindent1">• Unclear etiology: consider initiation of empiric bacterial meningitis treatment while observing and awaiting CSF studies</p>
<p class="h1cr"><a id="page_6-12" class="calibre8"></a>E<small class="calibre31">NCEPHALITIS</small> <span class="r3">(</span><span class="r4">NEJM</span> <span class="r3">2018;379:557)</span></p>
<p class="h">Definition</p>
<p class="noindent1">• Inflammation of brain parenchyma characterized by impaired cerebral function (AMS, neurologic deficits) often due to primary viral infection or post-viral inflammation</p>
<p class="h">Etiologies <span class="r">(specific etiology found in &lt;20% of cases;</span> <span class="r2">Neurology</span><span class="r1"> 2006;66:75;</span> <span class="r2">CID</span><span class="r1"> 2008;47:303)</span></p>
<p class="noindent1">• <b class="calibre7">HSV-1</b> all ages/seasons. If sxs recur after Rx, consider viral relapse vs. autoimmune encephalitis b/c high rates of autoimmune disease wks later <span class="r1">(</span><span class="r2">Lancet Neurol</span> <span class="r1">2018;17:760)</span>.</p>
<p class="noindent1">• <b class="calibre7">VZV</b> 1° or reactivation; ± vesicular rash; all ages (favors elderly), all seasons</p>
<p class="noindent1">• <b class="calibre7">Arboviruses:</b> evaluate for exposure to vector/geography. Mosquitoes: West Nile, Eastern/Western equine, St. Louis, La Crosse; Ixodes tick: Powassan.</p>
<p class="noindent1">• Enteroviruses (coxsackie, echo): preceding URI/ GI sx; peaks in late summer/early fall</p>
<p class="noindent1">• Other infectious: CMV, EBV, HIV, JC, measles, mumps, rabies, adeno, influenza, Lyme</p>
<p class="noindent1">• Non-infectious: autoimmune/paraneoplastic (anti-NMDAR, anti-Hu, anti-Ma2, anti-CRMP5, anti-mGluR5), post-infxn demyelination (eg, ADEM)</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Fever</b> + <b class="calibre7">ΔMS</b> (subtle to severe), seizure, focal neuro deficit, HA in meningoencephalitis</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2013;57:1114)</span></p>
<p class="noindent1">• CSF analysis: <b class="calibre7">lymphocytic pleocytosis</b>; PCR for HSV (95% Se &amp; Sp), VZV; consider other PCR based on risk factors (CMV/EBV, HIV, JC, adeno/enterovirus, WNV)</p>
<p class="noindent1">• Consider testing for autoimmune etiologies and serologic viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric HSV/VZV Rx</p>
<p class="noindent1">• <b class="calibre7">MRI</b> (CT if unavailable); HSV temporal lobe; W. Nile &amp; Powassan thalamic hyperintensity</p>
<p class="noindent1">• EEG to r/o seizure; findings in encephalitis are nonspecific (temporal lobe focus in HSV)</p>
<p class="h">Treatment</p>
<p class="noindent1">• HSV/VZV: IV acyclovir 10 mg/kg IV q8h; consider <i class="calibre6">empiric treatment</i> given frequency</p>
<p class="h1cr">B<small class="calibre31">ELL</small>’<small class="calibre31">S</small> P<small class="calibre31">ALSY</small></p>
<p class="h">Definition &amp; clinical manifestations</p>
<p class="noindent1">• Acute idiopathic unilat. <b class="calibre7">facial nerve palsy</b> (CN VII), often presumed HSV reactivation</p>
<p class="noindent1">• P/w unilateral facial muscle weakness, hyperacusis, ↓ taste, lacrimation, &amp; salivation</p>
<p class="noindent1">• Risk factors: pregnancy (preeclampsia), obesity, HTN, diabetes, preceding URI</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">Otol Head Neck Surg</span> <span class="r1">2013;149:656)</span></p>
<p class="noindent1">• Labs, imaging, EMG not needed in routine cases</p>
<p class="noindent1">• Ddx: Bilateral: Lyme, GBS, sarcoid. Additional neuro sx: stroke, tumor. Rash: herpes zoster. Other: otitis media, HIV, Sjögren.</p>
<p class="h">Treatment and Prognosis <span class="r1">(</span><span class="r2">CMAJ</span> <span class="r1">2014;186:917)</span></p>
<p class="noindent1">• 70% recover spontaneously w/in 6 mos, &gt;80% recover with glucocorticoid treatment</p>
<p class="noindent1">• Oral corticosteroids started w/in 72 hrs of sx onset improve odds of recovery; dose varies based on severity (House-Brackmann grading). No conclusive data on antivirals.</p>
<p class="noindent1">• If eyelid closure is compromised, eye protection is crucial to prevent trauma</p>
<p class="h1cr">H<small class="calibre31">ERPES</small> Z<small class="calibre31">OSTER</small> (S<small class="calibre31">HINGLES</small>)</p>
<p class="h">Definition &amp; etiology</p>
<p class="noindent1">• Painful vesicular rash in a peripheral nerve distribution due to reactivation of VZV</p>
<p class="noindent1">• Spread by contact with active lesion (prior to crusting) in uncomplicated zoster or via airborne transmission in disseminated zoster</p>
<p class="h">Clinical manifestations &amp; complications</p>
<p class="noindent1">• <b class="calibre7">Uncomplicated</b>: pain in a dermatomal distribution → dermatomal eruption of erythematous papules → vesicles → crusted plaques in varying stages of evolution</p>
<p class="noindent1">• <b class="calibre7">Disseminated</b>: vesicles across multiple dermatomes, visceral organ involvement (pneumonia, hepatitis, CNS) seen in immunosupp. (eg, transplant, malignancy)</p>
<p class="noindent1">• <b class="calibre7">Zoster opthalmicus</b>: ocular involvement (V1 of CN V) requires <b class="calibre7"><i class="calibre6">urgent ophtho eval</i></b></p>
<p class="noindent1">• Post-herpetic neuralgia: neuropathic pain lasting &gt;90 d after dx</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Clinical diagnosis if uncomplicated. Confirm with PCR (most sensitive), DFA, and viral culture (allows for resistance testing) of vesicular fluid (scrape from unroofed vesicle).</p>
<p class="h">Treatment &amp; prevention</p>
<p class="noindent1">• Uncomplicated: acyclovir, valacyclovir, or famciclovir x 7 d; initiate w/in 72 h of onset for greatest benefit; consider after 72 h if new lesions present; minimal benefit after crusting</p>
<p class="noindent1">• Superimposed bacterial cellulitis is common; if suspected, treat with appropriate antibiotics</p>
<p class="noindent1">• Disseminated/immunosupp.: IV acyclovir, eval for visceral spread, droplet precautions</p>
<p class="noindent1">• Prevention: Shingrix (2 doses) for all Pts &gt;50; consider in younger if immunosupp.</p>
<h2 class="ct"><a id="h91" class="calibre8"></a><a id="page_6-13" class="calibre8"></a><a href="part0003.html#rh100" class="calibre8">BACTEREMIA &amp; ENDOCARDITIS</a></h2>
<p class="h1cr">B<small class="calibre31">ACTEREMIA</small></p>
<p class="h">Definitions</p>
<p class="noindent1">• 1° bacteremia: bloodstream infection due to direct inoculation of the blood</p>
<p class="noindent1">• Central line associated bloodstream infection (CLABSI): bacteremia in which the same organism is growing from peripheral and catheter cultures <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2009;49:1)</span></p>
<p class="noindent1">• 2° bacteremia: infection of another site (eg, UTI, PNA, colitis, etc.) spreading to blood</p>
<p class="noindent1">• Contaminant: bacteria growing in a blood culture that does not represent a true infection</p>
<p class="h">Risk factors for bloodstream infections <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2012;308:502;</span> <span class="r2">CID</span><span class="r1">;2020;71)</span></p>
<p class="noindent1">• Syndromes with high likelihood of bacteremia:</p>
<p class="noindent2">Sepsis</p>
<p class="noindent2">Endovascular infxns: endocarditis, infection of pacemaker, vascular graft or IV catheter</p>
<p class="noindent2">Vertebral osteomyelitis, epidural abscess, septic arthritis</p>
<p class="noindent1">• Risk factors: indwelling lines, IVDU, immunosupp. (neutropenic, transplant)</p>
<p class="noindent1">• Organisms</p>
<p class="noindent2"><b class="calibre7">More likely pathogenic</b>: <i class="calibre6">S. aureus</i>, β-hemolytic strep, enterococci, GNR, <i class="calibre6">S. pneumo, Neisseria, Candida</i></p>
<p class="noindent2"><b class="calibre7">Less likely pathogenic</b>: coag-neg staph, diphtheroids, <i class="calibre6">Cutibacterium</i></p>
<p class="noindent1">• Time to growth: &lt;24 h → higher risk, &gt;72 h → lower risk (except slow-growing, eg, HACEK)</p>
<p class="noindent1">• <b class="calibre7">Factors increasing likelihood of endocarditis:</b> high-grade bacteremia w/o source, persisting after line removal or drainage of focal source, in hosts at risk for endocarditis or w/ organisms known to cause IE; emboli</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• ≥2 sets BCx prior to abx (set = aerobic + aneaerobic cx) at separate puncture sites</p>
<p class="noindent1">• If proven bacteremia, daily surveillance cxs until 48 hrs of ⊖ cxs. May not need for GNRs <span class="r1">(</span><span class="r2">ClD</span> <span class="r1">2017;65:1776)</span>.</p>
<p class="noindent1">• TTE/TEE if concern for endocarditis (see IE section)</p>
<p class="noindent1">• TTE and urgent ophthalmology evaluation if yeast is growing in BCx</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2009;49:1;</span> <span class="r2">JAMA</span> <span class="r1">2020;323:2160)</span></p>
<p class="noindent1">• Empiric abx based on Gram stain, cx, &amp; clinical syndrome, then tailor based on sensi</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Short-Term Central Venous Catheter-Related Bloodstream Infxns</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">S. aureus</i></b></p></td>
<td class="th1"><p class="tbodyh">Risk of endocarditis in bacteremia: ~25% <span class="sm">(<i class="calibre6">JACC</i> 1997;30:1072)</span>.</p>
<p class="tbodyh">ID consult a/w ↓ mortality <span class="sm">(<i class="calibre6">ClD</i> 2015;60:1451)</span>.</p>
<p class="tbodyh">Remove CVC, evaluate for endocarditis, osteo, hardware infections.</p>
<p class="tbodyh">Preferred abx: <i class="calibre6">MSSA</i> → nafcillin, oxacillin, or cefazolin. <i class="calibre6">MRSA</i> → vancomycin. Duration: 2 wks if normal host, no implants, no e/o endocarditis or metastatic complications. Otherwise 4–6 wks.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Coag-neg staphylococci</b></p></td>
<td class="th1"><p class="tbodyh">CVC retention does not ↓ rate of resolution, but a/w ↑ rate of recurrence <span class="sm">(<i class="calibre6">CID</i> 2009;49:1187)</span>. If CVC left, treat 10–14 d; if removed 5–7d.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7"><i class="calibre6">Enterococcus</i></b></p></td>
<td class="th1"><p class="tbodyh">Remove CVC &amp; treat for 7–14 d</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">GNR</b></p></td>
<td class="th1"><p class="tbodyh">Remove CVC esp if <i class="calibre6">Pseudomonas.</i> Rx for 14 d (7 if uncomplicated).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Yeast</b></p></td>
<td class="th1"><p class="tbodyh">Remove CVC &amp; treat for 14 from first ⊖ BCx. ID consult a/w ↓ mortality.</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7">Persistently</b> ⊕ <b class="calibre7">BCx:</b> remove CVCs, look for metastatic infxn (endocarditis, septic arthritis, osteo), infected thrombosis, or prosthetic material (vascular graft, PPM)</p>
<p class="h1cr">B<small class="calibre31">ACTERIAL</small> E<small class="calibre31">NDOCARDITIS</small></p>
<p class="h">Definition</p>
<p class="noindent1">• Infection of endothelium of heart (including but not limited to the valves) including both prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE)</p>
<p class="h">Risk Factors</p>
<p class="noindent1">• <b class="calibre7">Abnormal valve</b> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">1997;277:1794;</span> <span class="r2">JACC</span> <span class="r1">2018;72:2443)</span></p>
<p class="noindent2"><i class="calibre6">High risk:</i> prior endocarditis, prosthetic valve or ring, some congenital heart disease (unrepaired cyanotic; shunt/conduit; prosthesis in past 6 mos), transplant heart, valvulopathy, VAD</p>
<p class="noindent2"><i class="calibre6">Medium risk:</i> previous rheumatic fever, non-rheumatic valve disease (including MVP w/ MR or thickened leaflet), HCM, bicuspid AoV</p>
<p class="noindent1">• <b class="calibre7">Risk of bacteremia:</b> IVDU, indwelling venous catheters, hemodialysis, prosthetic material in heart (eg, pacemaker, ICD, graft), poor dentition</p>
<p class="imaget"><a id="page_6-14" class="calibre4"></a><img src="../images/00089.jpeg" alt="" class="calibre5"/></p>
<p class="tfn"><sup class="calibre22"><a id="rfn141-a" class="calibre8"></a>a</sup>↑ risk w/ DM, indwelling lines, immunosupp. <sup class="calibre22"><a id="rfn141-b" class="calibre8"></a>b</sup>Cx ⊖ = abiotrophic strep, HACEK (<i class="calibre6">Haemophilus para-influenzae &amp; aphrophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella</i>), <i class="calibre6">T. whipplei, Bartonella, Coxiella, Chlamydia, Legionella, Brucella</i> (<i class="calibre6">JAMA</i> 2007;297:1354; <i class="calibre6">Annals</i> 2007;147:829; <i class="calibre6">J Clin Microbiol</i> 2012;50:216)</p>
<p class="h">Clinical manifestation <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:882)</span></p>
<p class="noindent1">• <b class="calibre7">Persistent bacteremia</b> → <b class="calibre7">fever</b> (80–90%), rigors, night sweats, anorexia, myalgias</p>
<p class="noindent1">• <b class="calibre7">Valvular or perivalvular infection</b> → <b class="calibre7">HF</b>, conduction abnormalities (eg, AVB)</p>
<p class="noindent1">• <b class="calibre7">Septic emboli</b>: stroke, embolic MI, renal/splenic/pulmonary infarcts, septic arthritis, osteo</p>
<p class="noindent1">• Immune complex phenomena: arthritis, glomerulonephritis</p>
<p class="noindent1">• Subacute endocarditis can present with subacute progressive “B” sx (fatigue, wt loss)</p>
<p class="h">Physical exam</p>
<p class="noindent1">• <b class="calibre7">Cardiac murmur</b> (85%), s/s of new HF (pulmonary edema, JVP elevation, edema)</p>
<p class="noindent1">• Skin/ocular changes (uncommon but highly specific)</p>
<p class="noindent2">Janeway lesions (painless hemorrhagic macules on palms/ soles due to septic emboli)</p>
<p class="noindent2">Osler’s nodes (painful nodules on pads of digits due to immune complex deposition)</p>
<p class="noindent2">Splinter hemorrhages in fingernails or toenails</p>
<p class="noindent2">Roth spots (retinal hemorrhages)</p>
<p class="noindent1">• MSK: point tenderness along spine, red/hot joints</p>
<p class="noindent1">• Neurologic deficits c/f embolic stroke; vertebral tenderness c/f osteo or epidural abscess</p>
<p class="noindent1">• Devices: evaluate CVCs, PM/ICD pocket, and sites of other hardware/ prosthetics</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2010;51:131;</span> <span class="r2">EHJ</span> <span class="r1">2015;36:3075;</span> <span class="r2">Circ</span><span class="r1"> 2015;132:1435)</span></p>
<p class="noindent1">• <b class="calibre7">Blood cultures</b> (<i class="calibre6">before abx</i>): 3 sets (aerobic &amp; anaerobic bottles) from different sites, ideally spaced ≥1 h apart. ✓ BCx (at least 2 sets) after appropriate abx have been initiated to document clearance; repeat q24–48h until ⊖.</p>
<p class="noindent1">• Serial <b class="calibre7">ECGs</b> to assess for conduction disease and ↑ PR interval (c/f perivalvular abscess)</p>
<p class="noindent1">• <b class="calibre7">Echocardiogram:</b> TTE in all Pts. <b class="calibre7">TEE</b> if (i) TTE abnl but nondx, (ii) TTE ⊖ but high suspicion, (iii) complications suspected or present (eg, AVB), (iv) high-risk (prosthetic valve, CIED, prior IE, congenital heart dis.), (v) <i class="calibre6">S. aureus</i>, enterococcus, or fungus, (vi) Δ in signs or sx (eg, new conduction abnl, regurgitation, etc.) (vii) if considering a shortened course (10–14 d) of abx (vide infra)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1" colspan="3"><p class="tbodyc"><b class="calibre7">Sensitivity</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">NVE</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">PVE</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Abscess</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Transthoracic (TTE)</b></p></td>
<td class="th1"><p class="tbodyc">39–58%</p></td>
<td class="th1"><p class="tbodyc">33%</p></td>
<td class="th1"><p class="tbodyc">18–63%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Transesophageal (TEE)</b></p></td>
<td class="th1"><p class="tbodyc">&gt;90%</p></td>
<td class="th1"><p class="tbodyc">86%</p></td>
<td class="th1"><p class="tbodyc">76–100%</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">Mayo Clin Proc</i> 2014;89:799; <i class="calibre6">Circ</i> 2015;132:1435; <i class="calibre6">Eur Radiol</i> 2015; 25:2125; <i class="calibre6">J Am Soc Echo</i> 2016;29:315)</p>
<p class="noindent1">• Gated cardiac CT useful if TTE/TEE equivocal or suspected paravalvular abscess</p>
<p class="noindent1">• PET/CT using FDG useful for suspected PVE or CIED infxn if TTE/TEE equivocal</p>
<p class="noindent1">• Brain/spine imaging if concern for CNS spread (mycotic aneurysms, embolic stroke) or spinal involvement (vertebral osteo, epidural abscess)</p>
<p class="noindent1">• <b class="calibre7">Cx</b> ⊖ <b class="calibre7">endocarditis:</b> may be due to abx prior to BCx. PCR, bacterial 16S ribosomal RNA, serol. may be helpful. Detailed hx: animal exposure, travel, unpast. dairy, etc. ID eval. Consider organisms listed in Cx ⊖ footnote in microbiology table (vide supra).</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><a id="page_6-15" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Modified Duke Criteria</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbodyh"><b class="calibre7">Definitive</b>: 2 major <i class="calibre6">or</i> 1 major+3 minor <i class="calibre6">or</i> 5 minor; <b class="calibre7">Possible</b>: 1 major+1 minor <i class="calibre6">or</i> 3 minor</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Major</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Minor</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tnl"><span class="tft">•</span> <b class="calibre7">BCx</b> with common endocarditis pathogen (grown in 2 separate cx)</p>
<p class="tnl"><span class="tft">•</span> <i class="calibre6">Coxiella</i> serology ≥1:800</p>
<p class="tnl"><span class="tft">•</span> <b class="calibre7">Endocardial involvement</b>: vegetation, abscess, prosthetic dehiscence or <b class="calibre7">new valvular regurgitation</b></p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> Predisposing condition (see risk factors)</p>
<p class="tnl"><span class="tft">•</span> Fever</p>
<p class="tnl"><span class="tft">•</span> Vascular phenomena: septic arterial or pulmonary emboli, mycotic aneurysms, ICH, Janeway lesions</p>
<p class="tnl"><span class="tft">•</span> Immune phenomena: ⊕ RF, GN, Osler’s nodes, Roth spots</p>
<p class="tnl"><span class="tft">•</span> ⊕ BCx not meeting major criteria</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Se ~90%, Sp &gt;95%, NPV ≥92% (<i class="calibre6">CID</i> 2000;30:633).</p>
<p class="h">Treatment <span class="r1">(ID consult is strongly recommended)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Treatment</b> <span class="sm">(<i class="calibre6">Circ</i> 2015;132:1435)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Empiric</b></p></td>
<td class="th1"><p class="tbodyh">NVE or PVE &gt;12 mos post-op: vanc + CTX</p>
<p class="tbodyh">PVE &lt;12 mos post op: vanc + CTX ± gentamicin (if OK renal fxn)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Strep</i></p></td>
<td class="th1"><p class="tbodyh">Penicillin, ampicillin, cftx; if PVE consider gentamicin in discussion w/ ID</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Staph (S. aureus</i> and <i class="calibre6">lugdunensis)</i></p></td>
<td class="th1"><p class="tbodyh">MRSA: vanc or dapto</p>
<p class="tbodyh">MSSA: nafcillin, oxacillin, or cefazolin (avoid if CNS involvement due to poor penetration); vanc inferior to β-lactam for MSSA</p>
<p class="tbodyh">For PCN allergy w/ MSSA consider desensitization</p>
<p class="tbodyh">Consider rifampin / gentamicin in PVE in discussion w/ ID</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Enterococci</i></p></td>
<td class="th1"><p class="tbodyh">Ampicillin + [CTX or gent]; if VRE: linezolid, dapto, ampicillin if sensitive</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Gram negatives</p></td>
<td class="th1"><p class="tbodyh">HACEK: CTX, ampicillin or FQ. <i class="calibre6">Pseudomonas</i>: 2 anti-Pseudomonal agents [eg, β-lactam + (aminoglycoside or FQ)]</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Fungi (candida, aspergillus)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Candida</i>: amphotericin B ± flucytosine or micafungin</p>
<p class="tbodyh"><i class="calibre6">Aspergillus</i>: amphotericin B or voriconazole</p>
<p class="tbodyh">Ophtho consult for fungemia to rule out endophthalmitis</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• De-escalate abx to organism-directed therapy based on speciation and sensitivities</p>
<p class="noindent1">• If on anticoagulation or antiplatelet, typically can continue unless concern for stroke, intracranial hemorrhage, or need for emergent surgery</p>
<p class="noindent1">• Monitor for complications of endocarditis (CHF, conduction block, osteomyelitis, new embolic phenomenon) which can occur even on abx</p>
<p class="noindent1">• Duration is usually <b class="calibre7">4–6 wks</b></p>
<p class="noindent2">After ≥10d IV abx can consider ∆’ing to PO if clinically appropriate and available PO abx in consultation with ID <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:415)</span></p>
<p class="noindent2">Uncomplicated right-sided NVE or PCN-S <i class="calibre6">Strep</i> spp → 2 wks may be adequate</p>
<p class="noindent1">• IVDU-associated best managed by multidisciplinary teams including Addiction Medicine</p>
<p class="h">Indications for surgery <span class="r1">(consult early;</span> <span class="r2">JTCS</span><span class="r1"> 2017;153:1241;</span> <span class="r2">Circ</span> <span class="r1">2021;143:e72)</span></p>
<p class="noindent1">• Emergent if refractory cardiogenic shock</p>
<p class="noindent1">• Urgent (during initial hospitalization):</p>
<p class="noindent2"><b class="calibre7">Sx HF</b></p>
<p class="noindent2"><b class="calibre7">Penetrating infection</b>: periannular abscess, heart block, fistula, worsening conduction</p>
<p class="noindent2"><b class="calibre7">Persistent infection</b>: ⊕ BCx after &gt;5 d of appropriate abx, ↑ or ? large vegetation</p>
<p class="noindent2"><b class="calibre7">Emboli</b>: recurrent or w/ residual large (&gt;10 mm) vegetation &amp; severe AR/MR. Cerebral emboli <i class="calibre6">not</i> contraindic. unless severe stroke or hemorrhage <span class="r1">(</span><span class="r2">Stroke</span> <span class="r1">2006;37:2094)</span>.</p>
<p class="noindent2"><i class="calibre6">S. aureus</i>, fungal or multiRx-resistant organisms</p>
<p class="noindent2">PVE (emergent if dysfunction or dehiscence)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Endocarditis Prophylaxis</b> <span class="sm">(<i class="calibre6">Circ</i> 2007;116:1736)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiac conditions<sup class="calibre27"><a id="fn145-s1" class="calibre8"></a><a href="part0012.html#rfn145-s1" class="calibre8">*</a></sup></b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Prosthetic valve; previous endocarditis; congenital heart disease</b> (CHD) including unrepaired or incompletely repaired cyanotic CHD (palliative shunts or conduits), 1<sup class="calibre27">st</sup> 6 mo after completely repaired CHD using prosthetic material; cardiac transplant recipients w/ valvulopathy.</p>
<p class="tbody">(Prophylaxis no longer rec. in acquired valvular dysfxn, bicuspid AoV, MVP with leaflet thickening or regurgitation, HCM.)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Procedures<sup class="calibre27"><a href="part0012.html#rfn145-s1" class="calibre8">*</a></sup></b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Dental:</b> manipulation of gingival tissue or periapical region of teeth or perf oral mucosa (eg, extraction, periodontal, implant, root canal, cleaning)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Regimens</b></p></td>
<td class="th1"><p class="tbody">Oral: <b class="calibre7">amoxicillin 2 g 30–60 min before</b></p>
<p class="tbody">Unable to take PO: amp 2 g IM/IV or cefazolin or CTX 1 g IM/IV</p>
<p class="tbody">PCN-allergic: cephalexin or azithro or claritho or doxy</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn145-s1" class="calibre8"></a><a href="part0012.html#fn145-s1" class="calibre8">*</a></sup>Pts should meet both indications (high-risk condition &amp; high-risk procedure) to qualify for Ppx</p>
<h2 class="ct"><a id="h92" class="calibre8"></a><a id="page_6-16" class="calibre8"></a><a href="part0003.html#rh101" class="calibre8">TUBERCULOSIS</a></h2>
<p class="h">Definitions</p>
<p class="noindent1">• <b class="calibre7">Primary</b>: new <i class="calibre6">Mycobacterium tuberculosis</i> (TB) in a naïve host; symptomatic or asymptomatic; 90% of infected normal hosts will never develop clinically evident disease</p>
<p class="noindent1">• <b class="calibre7">Latent</b>: well-controlled infection without clinical or radiographic evidence of active disease; can persist for years to decades</p>
<p class="noindent1">• <b class="calibre7">Reactivated</b>: activation of latent; more likely in the setting of immunosuppression.</p>
<p class="noindent1">• <b class="calibre7">Milliary</b>: disseminated lympho-hematogenous spread due to primary or reactivated TB</p>
<p class="noindent1">• <b class="calibre7">Multidrug-resistant (MDR):</b> resistant to isoniazid (INH) &amp; rifampin. Can occur as 1° infxn.</p>
<p class="noindent1">• <b class="calibre7">Extensively drug-resistant (XDR):</b> resistant to INH, rifampin (RIF), fluoroquinolones (FQ), and at least one of amikacin, kanamycin, or capreomycin</p>
<p class="h">Epidemiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1081)</span></p>
<p class="noindent1">• Transmission via aerosols; untreated active dx requires airborne isolation in healthcare facilities and community isolation measures; must involve local public health authorities</p>
<p class="noindent1">• Acquisition: residents/travel in TB-endemic area, IVDU, resident/worker in correctional facility or homeless shelter, close contact w/ active TB</p>
<p class="noindent1">• Reactivation: risk is 5% in first 2 yr, 5–10% overall; ↑ if HIV ⊕, immunosupp. (anti-TNF, steroids), ESRD, DM, cancer, transplant, malnourished, smoker, substance use disorder</p>
<p class="h">Screening for latent TB</p>
<p class="noindent1">• Whom to screen: high likelihood of exposure and/or high risk of progression to active disease including HIV ⊕ and prior to immunosuppression (pre-transplant or anti-TNF)</p>
<p class="noindent1">• Relies on host immune system, so limited Se in immunosuppressed individuals</p>
<p class="noindent1">• Nb, testing for host exposure &amp; immune response to TB, <b class="calibre7"><i class="calibre6">not whether TB active</i></b> (vide infra)</p>
<p class="noindent1">• Screening tests</p>
<p class="noindent2">IFN-γ release assays (IGRA): preferred test; Ag-stimulated IFN-γ release from Pt’s T-cells. ↑ Sp over TST/PPD in BCG vaccinated Pts.</p>
<p class="noindent2">Tuberculin skin test (TST/ PPD): inject purified protein intradermally, examine for wheal 48–72 hrs later. Interpret based on max diameter of induration, not erythema.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Size of Reaction</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Persons Considered to Have</b> ⊕ <b class="calibre7">Test</b> <span class="sm">(<i class="calibre6">NEJM</i> 2002;347:1860)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">&gt;5 mm</p></td>
<td class="th1"><p class="tbody">HIV ⊕ or immunosupp. (eg, prednisone 15 mg/d × &gt;1 mo)</p>
<p class="tbody">Close contacts of Pt w/ active TB; CXR c/w prior active TB</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">&gt;10 mm</p></td>
<td class="th1"><p class="tbody">All other populations with ↑ prevalance/risk. Healthcare workers, recent conversion (↑ induration by &gt;10 mm in 2 y).</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">&gt;15 mm</p></td>
<td class="th1"><p class="tbody">No risk factors</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">False ⊖</p></td>
<td class="th1"><p class="tbody">Faulty application, anergy (including from active TB), acute TB</p>
<p class="tbody">(2–10 wk to convert), acute non-TB mycobacteria (NTM), malignancy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">False ⊕</p></td>
<td class="th1"><p class="tbody">Improper reading, cross-reaction with NTM, BCG vaccination (although usually &lt;10 mm by adulthood)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Booster effect</p></td>
<td class="th1"><p class="tbody">↑ in duration b/c immunologic boost by prior skin test in prev sensitized individual (by TB, NTM, or BCG). Test ⊖ → ⊕ but <i class="calibre6">not</i> true conversion due to <i class="calibre6">recent</i> infxn. 2<sup class="calibre27">nd</sup> test true baseline. Can be 1 y after initial test.</p></td>
</tr>
</tbody>
</table>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:1211)</span></p>
<p class="noindent1">• <b class="calibre7">Constitutional symptoms are common in all manifestations, but may be absent</b></p>
<p class="noindent1">• <b class="calibre7">Primary TB pneumonia:</b> middle or lower lobe consolidation, ± effusion, ± cavitation</p>
<p class="noindent1">• TB pleurisy: pulmonary effusion ± pericardial and peritoneal effusions secondary to granuloma breakdown and local inflammation; can occur in primary or reactivation</p>
<p class="noindent1">• <b class="calibre7">Reactivation TB pulmonary disease</b>: upper lobe infiltrate ± volume loss ± cavitation</p>
<p class="noindent1">• <b class="calibre7">Milliary TB</b>: diffuse millet seed-sized lesions, more common in immunosupp.</p>
<p class="noindent1">• Extrapulmonary TB: lymphadenitis, pericarditis, peritonitis, CNS disease including meningitis, GU tract disease ± sterile pyuria, osteoarticular disease (vertebral = Pott’s disease), granulomatous hepatitis, splenitis, cutaneous disease</p>
<p class="noindent1">• TB and HIV: HIV ⊕ at ↑ risk infxn, reactivation (8–10%/yr without ART, higher w/ ↓ CD4), and progressive 1° infxn. CXR can be atypical espec. if CD4 ≤200 <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2005;293:2740)</span>.</p>
<p class="h">Diagnostics for active TB <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2017;64:11)</span></p>
<p class="noindent1">• <b class="calibre7">Pulmonary TB</b>: common CXR findings discussed above; induced sputum <b class="calibre7">AFB smear</b> &amp; <b class="calibre7">culture</b> (3 samples at least 8 h apart) ± NAAT/ PCR (GeneXpert); consider bronchoscopy + BAL ± transbronchial biopsy. GeneXpert can also detect RIF resistance (non-bloody sputum only). Sp 98%/Se 74%, independent of HIV status.</p>
<p class="noindent1">• <b class="calibre7">Extrapulmonary TB</b></p>
<p class="noindent2"><i class="calibre6">Pleural/pericardial effusions or ascites:</i> fluid sampling for AFB cx/smear, NAAT/ PCR, cell counts. Adenosine deaminase (ADA) can be ↑, best validated in ascites. Free INFγ can be elevated in pleural/ascitic fluid (not validated in pericardial effusions). Higher diagnostic yield with pleural/pericardial biopsies for disease at these sites.</p>
<p class="noindent2"><a id="page_6-17" class="calibre4"></a><i class="calibre6">CSF:</i> fluid sampling for AFB cx/smear (submit at least 10 mL), NAAT/PCR, cell count (lymphocyte predominanace), glucose (low), protein (high), ADA (high)</p>
<p class="noindent2"><i class="calibre6">Soft tissue:</i> tissue biopsy with AFB staining, pathology w/ granulomas</p>
<p class="h">Treatment of latent TB</p>
<p class="noindent1">• If screening test ⊕ and no risk factors, confirm prior to treatment; if ⊕ w/ risk factors, proceed to treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2017;64:11)</span>.</p>
<p class="noindent1">• <b class="calibre7">Prior to treatment of latent TB, active TB must be ruled out</b> with, at a minimum, ROS for symptoms (cough, fever, night sweats, weight loss), physical exam, and CXR (though may be normal in immunosupp.)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Scenario</b></p></td>
<td class="th"><p class="tbodyh"><b class="calibre7">Prophylaxis Regimen</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">PPD/IGRA ⊕ (regardless of HIV status)</p></td>
<td class="th1"><p class="tbodyh">1<sup class="calibre27">st</sup> line: Rifampin × 4 mo <i class="calibre6">or</i> INH/rifampin daily x 3 mos <i class="calibre6">or</i> INH/rifapentine weekly × 12 wks) <span class="sm">(<i class="calibre6">MMWR</i> 2020; 69:1)</span></p>
<p class="tbodyh"><i class="calibre6">Alternative:</i> INH + vitamin B<sub class="calibre17">6</sub> × 6–9 mos</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Contact case known or suspected to have MDR TB</p></td>
<td class="th1"><p class="tbodyh">No proven regimen: ? PZA + EMB, ? PZA + FQ</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• ✓ LFTs monthly if receiving INH (risk ↑ w/ age; <span class="r2">Chest</span> <span class="r1">2005;128:116</span>): if AST/ALT ↑ 5× ULN <i class="calibre6">or</i> sx (nausea, vomiting, abd pain) → stop TB meds &amp; re-eval</p>
<p class="h">Patient isolation</p>
<p class="noindent1">• Decision based on likelihood of active disease. Consider when cough, dyspnea, hemoptysis, ≥1 risk factor (HIV ⊕, foreign born, substance use disorder, homeless, recent incarceration, prior TB or exposure).</p>
<p class="noindent1">• Discontinue if alternative dx and AFB smear neg ×3, or TB treated for 2 wk &amp; AFB neg ×3</p>
<p class="h">Treatment of active tuberculosis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:2149;</span> <span class="r2">Lancet</span><span class="r1"> 2016;387:1211)</span></p>
<p class="noindent1">• Prior to treatment, <b class="calibre7">consult ID</b>, check LFTs, Cr, <b class="calibre7">HIV</b> &amp; hepatitis A/B/C screen, DM screen, pregnancy screen, vision testing for acuity and color, EtOH use history</p>
<p class="noindent1">• Treatment requires several drugs to prevent resistance (see below)</p>
<p class="noindent1">• <b class="calibre7">Suspect MDR TB</b> if prior TB Rx (esp. if poor adherence), travel to area w/ ↑ rates of MDR (India, China, Eastern Europe including Russia, South Africa), exposure to person w/ likely MDR-TB <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2008;359:636)</span></p>
<p class="noindent1">• “Paradoxical <i class="calibre6">worsening</i>” of sx can occur after starting Rx. More common w/ extrapulm. TB &amp; more frequent/severe w/ concurrent immune reconstitution (eg, HIV ⊕ Pts started on ART, Pts taken off immunosuppression). <b class="calibre7">Must r/o Rx failure</b> (repeat Cx, imaging), consider checking drug levels.</p>
<p class="noindent1">• Duration of treatment varies based on host, clinical manifestation, and improvement/ progression on treatment</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Antituberculous Medications</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drug</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Adverse Effects<sup class="calibre27"><a id="fn148-s1" class="calibre8"></a><a href="part0012.html#rfn148-s1" class="calibre8">*</a></sup></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Isoniazid (INH)</p></td>
<td class="th1"><p class="tbody">Hepatitis (avoid EtOH), periph neuropathy (↓ risk by suppl. vit B<sub class="calibre17">6</sub>), drug-induced lupus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Rifampin (RIF)</p></td>
<td class="th1"><p class="tbody">Orange tint of body fluids, GI upset, hepatitis (avoid EtOH), hypersensitivity, fever, drug interactions</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Pyrazinamide (PZA)</p></td>
<td class="th1"><p class="tbody">Hepatitis (avoid EtOH), hyperuricemia, arthritis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ethambutol (EMB)</p></td>
<td class="th1"><p class="tbody">Optic neuritis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Streptomycin (SM)</p></td>
<td class="th1"><p class="tbody">Ototoxicity, nephrotoxicity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Amikacin (AMK)</p></td>
<td class="th1"><p class="tbody">Ototoxicity, nephrotoxicity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Quinolone (moxifloxacin, levofloxacin)</p></td>
<td class="th1"><p class="tbody">GI upset, tendinopathy, ↑ QTc</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn148-s1" class="calibre8"></a><a href="part0012.html#fn148-s1" class="calibre8">*</a></sup>Risk of hepatitis ↑ w/ pre-existing liver disease. Consult ID, consider holding/replacing PZA or INH.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Scenario</b></p></td>
<td class="th"><p class="tbodyh"><b class="calibre7">Antituberculous Treatment Regimens</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary TB</b></p>
<p class="tbodyh">≥<b class="calibre7">4% INH-resist. in community</b> (incl. most of U.S.)</p></td>
<td class="th1"><p class="tbodyh">INH + RIF + PZA + EMB until suscept. known</p>
<p class="tbodyh">If <i class="calibre6">sensitive</i> to INH &amp; RIF → INH + RIF + PZA × 2 mo, <i class="calibre6">then</i> → INH + RIF × at least 4 mo</p>
<p class="tbodyh">If <i class="calibre6">resistant</i>, see next row</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Drug-resistant TB</b> (INH-R, RIF-R, or MDR/XDR)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Consult ID specialist</i></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 2008;359:636)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Extrapulmonary TB</b></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Consult ID specialist</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">TB in HIV</b> ⊕ <b class="calibre7">patient</b></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Consult ID specialist</i></p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h93" class="calibre8"></a><a id="page_6-18" class="calibre8"></a><a href="part0003.html#rh102" class="calibre8">HIV/AIDS</a></h2>
<p class="h">Definition &amp; Clinical Manifestations</p>
<p class="noindent1">• Acute HIV: rash, lymphadenopathy, fever, oral ulcers, pharyngitis, myalgias, diarrhea Presents ~2–6 wk after exposure; not all HIV infections result in symptoms of acute HIV</p>
<p class="noindent1">• AIDS: HIV + CD4 &lt;200/mm<sup class="calibre19">3</sup> <i class="calibre6">or</i> AIDS-defining opportunistic infection (OI) or malignancy</p>
<p class="h">Epidemiology</p>
<p class="noindent1">• <b class="calibre7">~</b>1.2 million Americans living w/ HIV (13% unaware); ~37 million worldwide</p>
<p class="noindent1">• <b class="calibre7">High risk groups:</b> MSM, transgender women, IVDU, sex worker, partners of high-risk Pts</p>
<p class="noindent1">• Transmission: sexual (risk 0.1–1% per sex act w/o ARV), needlesticks (occupational or IVDU), vertical (15–40% w/o ARV), transfusions, organ transplant (uncommon in U.S.)</p>
<p class="h">Prophylaxis <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:2237;</span> <span class="r2">Lancet</span> <span class="r1">2016;387:53;</span> <span class="r2">J Infect Dis</span> <span class="r1">2018;218:16; CDC 2021)</span></p>
<p class="noindent1">• <b class="calibre7">Pre-exposure</b> (PrEP): TDF/FTC daily, ↓ transmission &gt;90% if adherent. Consider for serodiscordant partners, condomless sex in high-risk groups, STI w/in 6 mo, IVDU w/ equipment sharing. <b class="calibre7">Rule out HIV prior to initiation</b>, ✓ renal fxn, STIs, &amp; HIV q3 mo.</p>
<p class="noindent1">• <b class="calibre7">Post-exposure</b> (PEP): start ASAP (within 72 hr) after high-risk exposure from HIV ⊕ source (case-by-case decision if HIV status ?). Test baseline HIV, STIs, HBV, HCV. Rx: 2 NRTIs (usually TDF/FTC) + RAL or DTG × 4 wks. Consider initiating PrEP afterwards.</p>
<p class="h">Screening and Diagnosis <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2018;320:379)</span></p>
<p class="noindent1">• Screen all 13–64 yo at least once, every preg, if new STI dx;<b class="calibre7"> screen high risk annually</b></p>
<p class="noindent1">• <b class="calibre7">HIV Ab/p24Ag</b> (ELISA assay): ⊕ 1–12 wk after acute infxn; &gt;99% Se; 1° screening test</p>
<p class="noindent1">• If ⊕, Ab differentiation assay confirms and differentiates HIV-1 vs. -2 <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2013;62:489)</span></p>
<p class="noindent1">• <b class="calibre7">HIV RNA PCR viral load (VL)</b> in plasma; assay range is 20–10 million copies/mL; false ⊕ can occur, but usually low # copies; in contrast, VL should be high (&gt;750 k) in 1° infxn</p>
<p class="noindent1">• <b class="calibre7">CD4 count:</b> not a dx test, b/c can be HIV ⊕ w/ normal CD4 or be HIV ⊖ w/ low CD4</p>
<p class="h">Approach to newly diagnosed HIV ⊕ Pt <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2020;73:e3572)</span></p>
<p class="noindent1">• Counsel re: excellent prognosis w/adherence to treatment, treatment options, &amp; disclosure</p>
<p class="noindent1">• <b class="calibre7">Lab evaluation:</b> CD4 count, HIV VL &amp; genotype, CBC w/ diff., BMP, LFTs, HbA1c, lipids, UA, PPD/ IGRA, syphilis Ab, <i class="calibre6">Chlamydia</i> &amp; gonorrhea (3 site), Hep A/B/C, G6PD (if high-risk ethnicity), preg screen, HLA-B*5701 if Rx w/ abacavir. If AIDS: CMV IgG, Toxo IgG.</p>
<p class="noindent1">• Confirm all vaccinations (including annual flu) are up to date, avoid live vax if CD4 ≤200</p>
<p class="noindent1">• <b class="calibre7">Initiate ARV early</b> (same day, preferably after labs/genotype and w/ <i class="calibre6">guidance from HIV specialist</i>) regardless of CD4 level because ↓ mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:795)</span></p>
<p class="noindent1">• <b class="calibre7">Treatment prevents transmission to partners.</b> Risk of transmission w/ unprotected sex w/ undetectable VL &gt;6 months is ~0% <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;316:171;</span> <span class="r2">Lancet</span><span class="r1"> HIV 2018;5:e438)</span>.</p>
<p class="noindent1">• Regimens include: 2 NRTI (eg, TAF + FTC) + <i class="calibre6">either</i> INSTI or boosted PI (eg, DRV/r)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyh"><b class="calibre7">Common Antiretrovirals (ARVs)</b></p></td>
<td class="th"><p class="tbodyh"><b class="calibre7">Common Side Effects</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">NRTI</b></p></td>
<td class="th1"><p class="tbodyh">abacavir (ABC; Ziagen)</p>
<p class="tbodyh">emtricitabine (FTC; Emtriva)</p>
<p class="tbodyh">lamivudine (3TC; Epivir)</p>
<p class="tbodyh">tenofovir (TAF or TDF)</p>
<p class="tbodyh">zidovudine (AZT; Retrovir)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Class:</i> GI intol, lipoatrophy, lactic acidosis</p>
<p class="tbodyh">ABC: hypersensitivity (3%), ✓ <b class="calibre7">HLA-B<sup class="calibre27">*</sup>570</b>1</p>
<p class="tbodyh">AZT: BM suppression (esp. macrocytic anemia)</p>
<p class="tbodyh">TDF: renal toxicity, bone density loss</p>
<p class="tbodyh">TAF: minimal renal toxicity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">NNRTI</b></p></td>
<td class="th1"><p class="tbodyh">efavirenz (EFV; Sustiva)</p>
<p class="tbodyh">etravirine (ETR; Intelence)</p>
<p class="tbodyh">nevirapine (NVP; Viramune)</p>
<p class="tbodyh">rilpivirine (RPV; Edurant)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Class:</i> rash, hepatitis, mixed CYP450 inducer/inhib</p>
<p class="tbodyh">EFV: CNS effects (incl depression)</p>
<p class="tbodyh">NVP: rash and hypersensitivity [risk factors are female, CD4 &gt;250, pregnancy (∴ avoid)]</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">PI</b></p></td>
<td class="th1"><p class="tbodyh">atazanavir (ATV; Reyataz)</p>
<p class="tbodyh">darunavir (DRV; Prezista)</p>
<p class="tbodyh">lopinavir (LPV; Kaletra)</p>
<p class="tbodyh"><i class="calibre6">PIs given w/boosters ritonavir or cobicistat for</i> ↑ <i class="calibre6">PK</i></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Class:</i> GI intol; hepatotoxicity; inhibit CYP450 (many DDIs, eg statins, steroids, DOACs); ↑ glc; hyperlipid (less w/ ATV); MI <span class="sm">(<i class="calibre6">NEJM</i> 2007;356:1723)</span></p>
<p class="tbodyh">ATV: crystalluria → nephrolithiasis</p>
<p class="tbodyh">DRV: rash (10%); possible sulfa cross-reactivity</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">EI</b></p></td>
<td class="th1"><p class="tbodyh">maraviroc (MVC; Selzentry)</p></td>
<td class="th1"><p class="tbodyh">Dizziness, hepatotoxicity; ✓ CCR5 tropism assay</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">INSTI</b></p></td>
<td class="th1"><p class="tbodyh">bictegravir (BIC; Biktarvy) dolutegravir (DTG; Tivicay)</p>
<p class="tbodyh">elvitegravir (EVG; Vitekta)</p>
<p class="tbodyh">raltegravir (RAL; Isentress)</p>
<p class="tbodyh">cabotegravir (CAB; Vocabria)</p></td>
<td class="th1"><p class="tbodyh">Class: diarrhea; weight gain; ↑ CPK</p>
<p class="tbodyh">DTG/BIC ↑ metformin levels; monitor glc</p>
<p class="tbodyh">DTG a/w 0.003% risk of neural tube defects <span class="sm">(<i class="calibre6">NEJM</i> 2019;381:827)</span></p>
<p class="tbodyh">CAB/RPV: injection site rxn</p></td>
</tr>
</tbody>
</table>
<p class="tfn">NRTI, nucleoside/tide reverse transcriptase inhib; NNRTI, nonnucleoside RTI; PI, protease inhib; EI, entry inhib (CCR5 antagonist); INSTI, integrase inhib; several multiclass combo pills exist</p>
<p class="noindent1">• Initiation of ARVs may <i class="calibre6">transiently worsen</i> existing OIs (TB, MAC, CMV, others) due to immune reconstitution inflammatory syndrome (IRIS). Prednisone during 1<sup class="calibre19">st</sup> 4 wks of ARVs ↓ risk for TB-associated IRIS, but not routinely given <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:1915)</span>.</p>
<p class="noindent1">• <b class="calibre7">Do not start ARVs</b> immediately if c/f cryptococcal or TB meningitis</p>
<p class="noindent1"><a id="page_6-19" class="calibre4"></a>• After ARV initiation, check VL q4 wks until undetectable, then monitor q3–4 mos</p>
<p class="h">Approach to previously established HIV ⊕ Pt</p>
<p class="noindent1">• H&amp;P (mucocutaneous, neurocognitive, OIs, malignancies, STDs); meds and adherence</p>
<p class="noindent1">• Review ARVs (past and current); if hospitalized typically continue ARVs, if any must be held, <i class="calibre6">stop all</i> to ↓ risk of resistance</p>
<p class="noindent1">• Regimen failure: cannot achieve undetectable VL after months on ARVs, viral rebound (VL &gt;200 copies/mL ×2 after prior suppression), ↓ CD4 count or clinical worsening</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">OI Prophylaxis</b> (<a href="https://aidsinfo.nih.gov/guidelines" class="calibre4">https://aidsinfo.nih.gov/guidelines</a> &amp; <span class="sm"><i class="calibre6">JAMA</i> 2018;320:379, <a href="http://HIV.gov:2020" class="calibre4">HIV.gov:2020</a>)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">OI</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Indication</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">1° Prophylaxis</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Tuberculosis</p></td>
<td class="th1"><p class="tbody">⊕ PPD (≥5 mm), IGRA,</p>
<p class="tbody"><i class="calibre6">or</i> high-risk exposure</p></td>
<td class="th1"><p class="tbody">See treatment for latent TB</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><i class="calibre6">Pneumocystis jiroveci</i> (PCP)</p></td>
<td class="th1"><p class="tbody">CD4 &lt;200/mm <i class="calibre6">or</i> CD4 &lt;14% or thrush</p></td>
<td class="th1"><p class="tbody">TMP-SMX DS qd (first line) <i class="calibre6">or</i> dapsone qd <i class="calibre6">or</i> atovaquone qd <i class="calibre6">or</i> pentamidine inhaled q4wk</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Histoplasmosis</p></td>
<td class="th1"><p class="tbody">CD4 &lt;150/mm + endemic/ exposure</p></td>
<td class="th1"><p class="tbody">Itraconazole qd</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Toxoplasmosis</p></td>
<td class="th1"><p class="tbody">CD4 &lt;100/mm<sup class="calibre27">3</sup> <i class="calibre6">and</i> ⊕ <i class="calibre6">Toxo</i> IgG</p></td>
<td class="th1"><p class="tbody">TMP-SMX DS qd <i class="calibre6">or</i> dapsone 50 mg qd + pyrimeth. qwk + leucovorin 25 qwk</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">MAC</p></td>
<td class="th1" colspan="2"><p class="tbody">Ppx no longer rec. if effective ARVs initiated</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbody">When to stop Ppx: PCP and toxo if CD4 &gt;200 × 3 mos; Histo if CD4 &gt;150 × 6 mos</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">C<small class="calibre31">OMPLICATIONS</small> <small class="calibre31">OF</small> HIV/AIDS</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">CD4 Count</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Complications</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Any</b></p></td>
<td class="th1"><p class="tbody"><i class="calibre6">S. pneumo</i>, TB, VZV, HPV complications, Kaposi’s sarcoma, lymphoma, ↑ CVD risk, ↓ bone density.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;<b class="calibre7">500</b></p></td>
<td class="th1"><p class="tbody">Constitutional sx. Mucocutaneous: seborrheic dermatitis; psoriasis; oral hairy leukoplakia; HSV. Recurrent bacterial infxns.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;<b class="calibre7">200</b></p></td>
<td class="th1"><p class="tbody">PCP<i class="calibre6">, Toxo,</i> PML<i class="calibre6">, Crypto, candida, Histo/Coccidio</i> (endemic areas)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">&lt;<b class="calibre7">50–</b>1<b class="calibre7">00</b></p></td>
<td class="th1"><p class="tbody">CMV, MAC, CNS lymphoma, invasive aspergillosis, bacillary angiomatosis (dissem. <i class="calibre6">Bartonella</i>), death (&lt;50 is medical emergency)</p></td>
</tr>
</tbody>
</table>
<p class="h">Fever workup in patient with HIV/AIDS</p>
<p class="noindent1">• Etiologies <span class="r1">(</span><span class="r2">Infect Dis Clin North Am</span> <span class="r1">2007;21:1013)</span></p>
<p class="noindent2"><b class="calibre7">infxn</b> (82–90%): MAC, TB, CMV, early PCP, <i class="calibre6">Histo</i>, <i class="calibre6">Crypto</i>, <i class="calibre6">Coccidio</i>, <i class="calibre6">Toxo</i>, endocarditis</p>
<p class="noindent2"><b class="calibre7">noninfectious:</b> lymphoma, drug reaction. Non 1° HIV itself rarely (&lt;5%) cause of fever.</p>
<p class="noindent1">• Workup: guided by CD4 count, s/s, epi, &amp; exposures</p>
<p class="noindent2">CBC, BMP, LFTs, BCx, CXR, UA, mycobact. &amp; fungal cx, ✓ meds, ? ✓ chest &amp; abd CT</p>
<p class="noindent2">CD4 &lt;100–200 → serum crypto Ag, urinary <i class="calibre6">Histo</i> Ag, CMV PCR</p>
<p class="noindent2">pulmonary s/s → CXR; ABG; sputum for bacterial cx, PJ stain, AFB; bronchoscopy</p>
<p class="noindent2">diarrhea → stool cx, O&amp;P, AFB; direct visualization with bx on colonoscopy</p>
<p class="noindent2">cytopenias → BM bx for path &amp; cx of aspirate including for mycobacteria &amp; fungi</p>
<p class="noindent2">headache/visual Δs→ LP; send CSF for bacterial/fungal cx, CrAg, ? MTb PCR; send CMV PCR from serum; dilated eye exam with Ophtho</p>
<p class="h">Cutaneous</p>
<p class="noindent1">• Eosinophilic folliculitis; <b class="calibre7">warts</b> (HPV); HSV &amp; VZV; MRSA SSTI; scabies; candidiasis; eczema; prurigo nodularis; psoriasis; drug eruption; subungual onychomycosis</p>
<p class="noindent1">• Molluscum contagiosum (poxvirus): 2–5 mm pearly papules w/ central umbilication</p>
<p class="noindent1">• <b class="calibre7">Kaposi’s sarcoma</b> (KSHV or HHV8): red-purple nonblanching nodular lesions</p>
<p class="noindent1">• Bacillary angiomatosis (disseminated <i class="calibre6">Bartonella</i>): friable violaceous vascular papules</p>
<p class="h">Oral</p>
<p class="noindent1">• Aphthous ulcers; KS; <b class="calibre7">thrush/oral candidiasis</b> (curd-like patches, often painless)</p>
<p class="noindent1">• Oral hairy leukoplakia<b class="calibre7">:</b> painless proliferation of papillae w/ adherent white coating usually on lateral tongue, caused by EBV but not precancerous</p>
<p class="h">Ophthalmologic</p>
<p class="noindent1">• <b class="calibre7">CMV retinitis</b> (CD4 usu &lt;50); Rx: ganciclovir or valganciclovir, foscarnet, or cidofovir</p>
<p class="noindent1">• HZV, VZV, syphilis (any CD4 count, <i class="calibre6">treat as neurosyphilis</i>) or <i class="calibre6">Toxo</i> (CD4 usually &lt;100)</p>
<p class="h">Endocrine/metabolic</p>
<p class="noindent1">• Hypogonadism; adrenal insufficiency (CMV, MAC, TB, HIV, or med-related); sarcopenia; osteopenia/porosis/fragility fractures (at all CD4 counts)</p>
<p class="noindent1">• <b class="calibre7">Lipodystrophy</b>: central obesity, peripheral lipoatrophy, dyslipidemia, hyperglycemia</p>
<p class="h">Cardiovascular <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2013;61:511)</span></p>
<p class="noindent1">• Higher rates of CAD, stroke, VTE, dilated CMP; pulm. HTN; pericarditis/effusion</p>
<p class="h"><a id="page_6-20" class="calibre4"></a>Pulmonary</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Radiographic Pattern</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Common Causes</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Normal</p></td>
<td class="th1"><p class="tbody">Early PCP</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Diffuse interstitial infiltrates</p></td>
<td class="th1"><p class="tbody">PCP, TB, viral, or disseminated fungal</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Focal consolidation or masses</p></td>
<td class="th1"><p class="tbody">Bacterial or fungal, TB, KS</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cavitary lesions</p></td>
<td class="th1"><p class="tbody">TB, NTM, aspergillus, other fungal, bacterial (incl. <i class="calibre6">Staph aureus</i>, <i class="calibre6">Nocardia, Rhodococcus</i>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Pleural effusion</p></td>
<td class="th1"><p class="tbody">TB, bacterial or fungal, KS, lymphoma</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <b class="calibre7"><i class="calibre6">Pneumocystis jiroveci</i> (PCP) pneumonia</b> (CD4 &lt;200) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1990;323:1444)</span></p>
<p class="noindent2">fever, night sweats, dyspnea on exertion, dry (“doorstop”) cough</p>
<p class="noindent2">CXR w/ interstitial pattern, ↓ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>, ↑ A-a ∇, ↑ LDH, ⊕ PCP sputum stain, ⊕ β-glucan</p>
<p class="noindent2">Rx if P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &gt;70: TMP-SMX 15–20 mg of TMP/kg divided tid, avg dose = DS 2 tabs PO tid</p>
<p class="noindent2">Rx if P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &lt;70 or A-a gradient &gt;35: prednisone before abx (40 mg PO bid; ↓ after 5 d)</p>
<p class="noindent2">HIV ⊕ smokers much more likely to die from lung cancer than OI <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;177:1613)</span></p>
<p class="h">Gastrointestinal &amp; hepatobiliary</p>
<p class="noindent1">• Esophagitis: <i class="calibre6">Candida</i>, CMV (solitary, lg serpiginous), HSV (multiple, small shallow), giant aphthous ulcers, pills; EGD if no thrush or no response to empiric antifungals</p>
<p class="noindent1">• Enterocolitis: <i class="calibre6">bacterial</i> (esp. if acute: <i class="calibre6">Shigella</i>, <i class="calibre6">Salmonella</i>, <i class="calibre6">C. diff</i>); <i class="calibre6">protozoal</i> (esp. if chronic: <i class="calibre6">Giardia</i>, <i class="calibre6">Isospora</i>, <i class="calibre6">Cryptosporidium</i>, <i class="calibre6">Cyclospora</i>, <i class="calibre6">Microsporidium</i>, <i class="calibre6">Entamoeba</i>); <i class="calibre6">viral</i> (CMV, adeno); <i class="calibre6">fungal</i> (histo); MAC; AIDS enteropathy; TB enteritis</p>
<p class="noindent1">• GI bleeding: CMV, KS, lymphoma, histo; proctitis: HSV, CMV, <i class="calibre6">LGV, N. gonorrhoeae</i></p>
<p class="noindent1">• Hepatitis: HBV, HCV, CMV, MAC, TB, histo, drug-induced</p>
<p class="noindent1">• AIDS cholangiopathy: often a/w CMV or <i class="calibre6">Cryptosporidium or Microsporidium</i> (at ↓ CD4)</p>
<p class="h">Renal</p>
<p class="noindent1">• HIV-assoc. nephropathy (collapsing FSGS); <b class="calibre7">nephrotoxic drugs</b> (eg, TDF → prox tub dysfxn)</p>
<p class="h">Hematologic/oncologic <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1029)</span></p>
<p class="noindent1">• Cytopenia: ACD, BM infiltration by tumor/infxn (eg, MAC/TB), drug toxicity, hemolysis, ITP</p>
<p class="noindent1">• Non-Hodgkin lymphoma: ↑ frequency with any CD4 count, but incidence ↑ with ↓ CD4</p>
<p class="noindent1">• Hodgkin lymphoma (any CD4; impact of ART unclear)</p>
<p class="noindent1">• CNS lymphoma: CD4 count &lt;50, EBV-associated</p>
<p class="noindent1">• <b class="calibre7">Kaposi’s sarcoma</b> (HHV-8): at any CD4 count, incidence ↑ b/c CD4 ↓, usu. MSM</p>
<p class="noindent2"><i class="calibre6">Mucocut.</i> (violacious lesions); <i class="calibre6">pulmonary</i> (nodules, infiltrates, LAN); <i class="calibre6">GI</i> (bleed, obstruct.)</p>
<p class="noindent1">• Cervical/anal CA (HPV high risk in MSM)</p>
<p class="noindent1">• ↑ rates of liver CA (a/w HBV/HCV), gastric CA</p>
<p class="h">Neurologic/Psychologic</p>
<p class="noindent1">• <b class="calibre7">Meningitis</b>: <i class="calibre6">Crypto</i> (dx w/ CSF; serum CrAg 90% Se), bacterial (inc. <i class="calibre6">Listeria</i>), viral (HSV, CMV, 1° HIV), TB, histo, <i class="calibre6">Coccidio</i>, lymphoma; neurosyphilis (cranial nerve palsies)</p>
<p class="noindent1">• <b class="calibre7">Space-occupying lesions</b>: may present as HA, focal deficits or Δ MS. Workup: MRI, brain bx only if suspect non-<i class="calibre6">Toxo</i> etiology (<i class="calibre6">Toxo</i> sero ⊖) or no response to 2 wk of empiric anti-<i class="calibre6">Toxo</i> Rx (if <i class="calibre6">Toxo</i>, 50% respond by d3, 91% by d14; <span class="r2">NEJM</span> <span class="r1">1993;329:995</span>)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Etiology</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Imaging Appearance</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Diagnostic Studies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Toxoplasmosis</b></p></td>
<td class="th1"><p class="tbody">Enhancing lesions, typically in basal ganglia (can be multiple)</p></td>
<td class="th1"><p class="tbody">⊕ <i class="calibre6">Toxo</i> serology (Se ~85%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">CNS lymphoma</b></p></td>
<td class="th1"><p class="tbody">Enhancing ring lesion (single 60% of the time)</p></td>
<td class="th1"><p class="tbody">⊕ CSF PCR for EBV</p>
<p class="tbody">⊕ SPECT or PET scan</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Progressive multifocal leukoencephalopathy</b> (PML)</p></td>
<td class="th1"><p class="tbody">Multiple nonenhancing lesions in white matter</p></td>
<td class="th1"><p class="tbody">⊕ CSF PCR for JC virus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Other: abscess, nocardiosis, crypto, TB, CMV, HIV</p></td>
<td class="th1"><p class="tbody">Variable</p></td>
<td class="th1"><p class="tbody">Biopsy</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• HIV-assoc. dementia: depressive sx, impaired attention/concentration, psychomotor slowing</p>
<p class="noindent1">• Depression: ↑ rates of suicide/depression</p>
<p class="noindent1">• Myelopathy: infxn (CMV, HSV), cord compression (epidural abscess, lymphoma)</p>
<p class="noindent1">• Peripheral neuropathy: meds (esp 1<sup class="calibre19">st</sup> gen NRTIs), CMV, diabetes</p>
<p class="h">Disseminated <i class="calibre6">Mycobacterium avium</i> complex (DMAC)</p>
<p class="noindent1">• Fever, night sweats, wt loss, abd pain, diarrhea, pancytopenia. Can cause localized lymphadenitis. Rx: clarithro/azithro + ethambutol ± rifampin/rifabutin.</p>
<p class="h">Cytomegalovirus (CMV)</p>
<p class="noindent1">• Retinitis, esophagitis, colitis, hepatitis, neuropathies, encephalitis. CMV VL may be ⊖. Consider tissue biopsy. Rx: ganciclovir, valganciclovir, foscarnet, or cidofovir.</p>
<h2 class="ct"><a id="h94" class="calibre8"></a><a id="page_6-21" class="calibre8"></a><a href="part0003.html#rh103" class="calibre8">TICK-BORNE DISEASES</a></h2>
<p class="imaget"><img src="../images/00090.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">–: &lt;15%, +: 15–25%, ++: 25–50%, +++: 50–75%, ++++: &gt;75%</p>
<p class="center"><i class="calibre6">Tick prophylaxis: protective clothing, tick</i> ✓<i class="calibre6"> q24h, DEET/picardin, if bitten remove ASAP</i></p>
<p class="h1cr">L<small class="calibre31">YME</small> D<small class="calibre31">ISEASE</small></p>
<p class="h">Microbiology &amp; epidemiology</p>
<p class="noindent1">• Spirochete <i class="calibre6">B. burgdorferi</i> transmitted by <i class="calibre6">Ixodes scapularis</i> (deer tick)</p>
<p class="noindent1">• Humans contact ticks in low brush near wooded areas</p>
<p class="noindent1">• Infection usually requires tick attached &gt;36–48 h</p>
<p class="noindent1">• Most common vector-borne illness in U.S.; peak in summer in NE/Mid-Atlantic/Midwest</p>
<p class="noindent1">• Consider coinfection w/ <i class="calibre6">Anaplasma, Babesia, B. miyamotoi</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Clinical Manifestations</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Stage</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Manifestations</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Early localized</b> (w/in 1 month)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">General:</i> flu-like illness. <i class="calibre6">Derm</i> (~80%): <b class="calibre7">erythema migrans</b> (EM) = erythematous patch ± central clearing, ~6–38 cm.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Early disseminated</b></p>
<p class="tbodyc">(wks to mos)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">General:</i> fatigue, malaise, LAN, HA</p>
<p class="tbodyh"><i class="calibre6">Derm:</i> multiple EM lesions</p>
<p class="tbodyh"><i class="calibre6">Rheum</i> (~10%): migratory arthralgias &amp; myalgias</p>
<p class="tbodyh"><i class="calibre6">Neurologic</i> (~15%): cranial neuropathies (esp. CN VII), aseptic meningitis, mononeuritis multiplex (± pain), transverse myelitis</p>
<p class="tbodyh"><i class="calibre6">Cardiac</i> (~8%): heart block, myopericarditis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Late disseminated</b> (mos to yrs)</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Derm</i> (rare in U.S.)<i class="calibre6">:</i> acrodermatitis chronica atrophicans, panniculitis</p>
<p class="tbodyh"><i class="calibre6">Rheum</i> (~60%, espec. if not Rx’d): recurrent mono- or oligoarthritis of large joints (classically knee), synovitis</p>
<p class="tbodyh"><i class="calibre6">Neurologic</i> (rare!)<i class="calibre6">:</i> subacute encephalomyelitis, polyneuropathy</p></td>
</tr>
</tbody>
</table>
<p class="tfn">(<i class="calibre6">NEJM</i> 2014;370:1724; CID 2020; 72:e1)</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2020; 72:e1)</span></p>
<p class="noindent1">• Avoid testing without signs/symptoms</p>
<p class="noindent1">• <i class="calibre6">Early localized:</i> clinical dx if EM + possible exposure; no need for testing (often sero ⊖)</p>
<p class="noindent1">• <i class="calibre6">Early or late</i> d<i class="calibre6">isseminated:</i> 2-step testing</p>
<p class="noindent2">1<sup class="calibre19">st</sup> step: ELISA screen (some false ⊕, false ⊖ w/ early abx or &lt;6 wk after tick bite)</p>
<p class="noindent2">2<sup class="calibre19">nd</sup> step: if ⊕ ELISA, confirm with IgM/IgG Western blot (↑ Sp) or 2<sup class="calibre19">nd</sup> ELISA</p>
<p class="noindent1">• Serum testing is sufficient for diagnosis of Lyme CNS infection or Lyme arthritis, though consider CSF (Ab testing in parallel with serum) or joint fluid sampling (PCR) to rule out other causes and provide a more definitive diagnosis</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2020; 72:e1; IDSA 2021)</span></p>
<p class="noindent1">• <b class="calibre7">Prophylaxis</b>: doxycycline × 1 <i class="calibre6">only</i> if <i class="calibre6">all</i> of the following:</p>
<p class="noindent2">1) <i class="calibre6">Ixodes scapularis</i> tick attached ≥36 h</p>
<p class="noindent2">2) Local Lyme carriage in ticks ≥20%</p>
<p class="noindent2">3) Abx can be given w/in ≤72 h of tick bite</p>
<p class="noindent2">4) No contraindication to doxycycline (eg, preg, allergy, age &lt;8 y)</p>
<p class="noindent2">Regardless of Ppx, monitor for fever, flu-like sx, rash (erythema migrans) × 30 d</p>
<p class="noindent1">• <b class="calibre7">Treatment</b></p>
<p class="noindent2"><i class="calibre6">Isolated EM:</i> doxy × 10 d (alternative: cefurox or amox × 14 d or azithro × 7 d)</p>
<p class="noindent2"><i class="calibre6">Arthritis:</i> doxy × 28 d (alternative: cefurox or amox × 28 d)</p>
<p class="noindent2"><i class="calibre6">Carditis/meningitis:</i> CTX IV or doxy PO (based on severity/response) × 14–21 d</p>
<p class="noindent1">• Consider coinfection if severe/refractory sx, persistent fever, cytopenias</p>
<p class="noindent1">• Recurrent sx after abx are likely re-infection, <i class="calibre6">not</i> relapse <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:1883)</span></p>
<p class="h1cr">B<small class="calibre31">ABESIOSIS</small></p>
<p class="h"><b class="calibre7">Microbiology &amp; epidemiology</b> <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2012;61:505)</span></p>
<p class="noindent1">• <i class="calibre6">Babesia microti</i> (U.S.) transmitted by <i class="calibre6">Ixodes</i> ticks; also risk from blood transfusion</p>
<p class="noindent1"><a id="page_6-22" class="calibre4"></a>• Peak incidence summer in NE U.S. (esp. near coast, “Nantucket fever”), north-central MW</p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Typically 1–4 wks after tick exposure; &lt;9 wks if transfusion</p>
<p class="noindent1">• Range: asx/mild flu-like sx to severe DAT ⊖ <b class="calibre7">hemolytic anemia</b>/DIC, multiorgan failure</p>
<p class="noindent1">• Risk factors for severe dx: <b class="calibre7">asplenia</b>, ↓ cellular immunity, TNF inhib, ↑ age, pregnancy</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2021;72:e49)</span></p>
<p class="noindent1">• Symptoms + blood smear w/ intraerythrocytic parasites (ring forms)</p>
<p class="noindent1">• Degree of parasitemia = % infected RBC on smear (correlates roughly w/ severity)</p>
<p class="noindent1">• Repeat smears (q12–24h) if sx persist despite negative initial smear</p>
<p class="noindent1">• PCR serum if smear ⊖ (or unavailable) and clinical suspicion</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2021;72:e49)</span></p>
<p class="noindent1">• Atovaquone &amp; azithro preferred; clinda/quinine (more adverse events); call ID if severe</p>
<p class="noindent1">• Duration depends on host; immunosupp often need longer Rx</p>
<p class="noindent1">• Consider exchange transfusion if parasitemia &gt;10%, severe hemolysis/ end-organ failure</p>
<p class="h1cr">E<small class="calibre31">HRLICHIOSIS</small>/A<small class="calibre31">NAPLASMOSIS</small></p>
<p class="h">Microbiology &amp; epidemiology</p>
<p class="noindent1">• Gram ⊖ obligate intracellular bacterium; <b class="calibre7">human monocytic ehrlichiosis</b> (<i class="calibre6">E. chaffeensis</i>, HME); <b class="calibre7">human granulocytic anaplasmosis</b> (<i class="calibre6">A. phagocytophilum</i>, HGA)</p>
<p class="noindent1">• Transmission: HME by <i class="calibre6">Amblyomma americanum</i> (lone star tick)<i class="calibre6">, Dermacentor variabilis</i> (dog tick)<i class="calibre6">;</i> HGA by <i class="calibre6">Ixodes;</i> <b class="calibre7">HGA</b> in NE, mid-Atl, MN; <b class="calibre7">HME</b> in SE and south-central U.S.</p>
<p class="noindent1">• Peak incidence spring and early summer; can be transmitted by blood transfusion</p>
<p class="h">Clinical manifestations <span class="r1">(typically w/in 3 wks of tick exposure)</span></p>
<p class="noindent1">• Asx or nonspecific: <b class="calibre7">fever</b>, <b class="calibre7">myalgias</b>, malaise, HA, delirium; onset often acute</p>
<p class="noindent1">• Laboratory: leukopenia, thrombocytopenia, ↑ aminotransferases, ↑ LDH, ↑ CK</p>
<p class="noindent1">• Severe disease can be complicated by bacterial superinfection</p>
<p class="h">Diagnosis</p>
<p class="noindent1">• Intraleukocytic morulae on peripheral smear in acute infection; serum PCR ⊕ in acute infection and convalescence</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:1767)</span></p>
<p class="noindent1">• Start Rx based on clinical suspicion; definitive dx requires PCR (but not 100% Se)</p>
<p class="noindent1">• Doxycycline × 10 d; if Pt does not defervesce in ≤48 h, consider co-infection/alt dx</p>
<p class="h1cr">R<small class="calibre31">OCKY</small> M<small class="calibre31">OUNTAIN</small> S<small class="calibre31">POTTED</small> F<small class="calibre31">EVER</small> (RMSF)</p>
<p class="h">Microbiology &amp; epidemiology</p>
<p class="noindent1">• Infection with <i class="calibre6">Rickettsia rickettsii</i> (Gram ⊖ obligate intracellular bacterium)</p>
<p class="noindent1">• Transmitted by <i class="calibre6">D. variabilis, D. andersoni</i> (wood tick); peak in spring/early summer</p>
<p class="noindent1">• Occurs in mid-Atl, SE/south central U.S., mountain west, Mexico, Central &amp; S. America</p>
<p class="h">Clinical manifestations <span class="r1">(typically w/in</span> 1<span class="r1">–2 wks of tick exposure)</span></p>
<p class="noindent1">• Nonspecific: <b class="calibre7">fever</b>, <b class="calibre7">HA</b>, ΔMS, myalgias, N/V, occasionally abdominal pain</p>
<p class="noindent1">• Rash (2–5 d <i class="calibre6">after</i> onset of fever) = <i class="calibre6">centripetal:</i> starts on ankles and wrists → trunk, palms, &amp; soles; progresses from macular to maculopapular to petechial</p>
<p class="noindent1">• Severe cases → vasculitis, multi-organ failure, meningoencephalitis; more likely in elderly</p>
<p class="h">Diagnosis <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2016;65:1)</span></p>
<p class="noindent1">• Clinical dx (often w/o rash initially); <i class="calibre6">requires high suspicion</i> given risk of delayed Rx</p>
<p class="noindent1">• Acute illness: skin bx for rickettsiae (Se 70–90%), consider ✓serologies (may be ⊖)</p>
<p class="noindent1">• Confirm dx: re-check serology 14–21 d later, ⊕ if 4-fold ↑</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">MMWR</span> <span class="r1">2016;65:1)</span></p>
<p class="noindent1">• Doxy × 7–10 d, empiric Rx if suspicion; if does not defervesce in ≤48 h ? co-infection/alt dx</p>
<p class="h1cr">T<small class="calibre31">ULAREMIA</small></p>
<p class="h">Microbiology</p>
<p class="noindent1">• Infxn w/ <i class="calibre6">Francisella tularensis</i> bacteria via arthropod bites, animal contact (bite, scratch, lick), contaminated food or water, aresolized materials</p>
<p class="h">Clinical manifestations <span class="r1">(typically w/in 2–</span>1<span class="r1">0 d of exposure)</span></p>
<p class="noindent1">• Fever, chills, malaise, HA, nausea, myalgias; ulcer w/ black eschar at site of entry; LAN; conjunctivitis; pharyngitis; PNA</p>
<p class="h">Diagnosis &amp; treatment</p>
<p class="noindent1">• Serology should be collected at presentation and 2 wks later, bacteria difficult to culture</p>
<p class="noindent1">• FLQ for mild infection, aminoglycoside for severe infection in consultation with ID</p>
<h2 class="ct"><a id="h95" class="calibre8"></a><a id="page_6-23" class="calibre8"></a><a href="part0003.html#rh104" class="calibre8">FEVER SYNDROMES</a></h2>
<p class="center"><i class="calibre6">Temperature ≥100.4°F or ≥38°C</i></p>
<p class="h">Diagnostic approach</p>
<p class="noindent1">• Thorough history including ROS, PMH/PSH, immunizations, including from childhood</p>
<p class="noindent1">• <b class="calibre7">Fever curve</b> (holding antipyretics); look at trend/pattern. Less likely to mount fever if: ESRD/ESLD, extremes of age, protein calorie malnutrition, immunosupp., steroid use.</p>
<p class="noindent1">• <b class="calibre7">Exposures</b>: travel, occupation/hobbies, animals, sexual contacts, TB. Consider geography, season, and incubation time in relation to exposures.</p>
<p class="noindent1">• <b class="calibre7">Physical exam</b>: look for thrush, dental caries; full eye exam; cardiac murmurs; HSM; abd tenderness; rash/skin lesions; LAN; synovitis; complete neuro exam</p>
<p class="h1cr">F<small class="calibre31">EVER</small> <small class="calibre31">OF</small> U<small class="calibre31">NKNOWN</small> O<small class="calibre31">RIGIN</small> (FUO)</p>
<p class="h">Definition &amp; etiologies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2022;386:463)</span></p>
<p class="noindent1">• <b class="calibre7">Fever</b> (as per above def) on &gt;1 occasion during ≥3 wk &amp; <b class="calibre7">no dx</b> despite 1 wk of evaluation</p>
<p class="noindent1">• More likely to be <i class="calibre6">unusual manifestation of common disease</i> than an uncommon disease</p>
<p class="noindent1">• In Pts with HIV: &gt;75% causes are infectious, but <i class="calibre6">rarely due to HIV itself</i></p>
<p class="noindent1">• <i class="calibre6">Frequent reassessment needed</i> to identify focal signs and progression of disease</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Category</b></p></td>
<td class="th"><p class="tbodyh"><b class="calibre7">Etiologies of Classic FUO</b> <span class="sm">(<i class="calibre6">Medicine</i> 2007;86:26; <i class="calibre6">AJM</i> 2015;128:1138)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Infection ~30%</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Tuberculosis:</b> disseminated or extrapulm. disease can have normal CXR, PPD/IGRA, sputum AFB; bx (lung, liver, bone marrow) for granulomas has 80–90% yield in milliary disease</p>
<p class="tbodyh"><b class="calibre7">Endocarditis:</b> if blood cxs neg consider Bartonella, Coxiella, et al.</p>
<p class="tbodyh">Abscess: dental, paraspinal, hepatic, splenic, subphrenic, pancreatic, -perinephric, pelvic, prostatic abscess or prostatitis, appendicitis</p>
<p class="tbodyh">Osteomyelitis, sinusitis, typhoid, 1° CMV or EBV, malaria, <i class="calibre6">Babesia</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Connective tissue disease ~30%</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Giant cell arteritis/</b>PMR<b class="calibre7">:</b> headache, scalp pain, jaw claudication, visual disturbances, myalgias, arthralgias, ↑ ESR</p>
<p class="tbodyh"><b class="calibre7">Adult-onset Still’s:</b> evanescent truncal rash, LAN, pharyngitis, ↑↑ ferritin</p>
<p class="tbodyh">PAN, ANCA ⊕, other vascul.; SLE, RA, psoriatic or reactive arthritis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Neoplasm ~20%</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Lymphoma:</b> LAN, HSM, ↓ Hct or plt, ↑ LDH; leukemia; myelodysplasia</p>
<p class="tbodyh"><b class="calibre7">Renal cell carcinoma:</b> microscopic hematuria, ↑ Hct</p>
<p class="tbodyh">HCC, pancreatic and colon cancers, sarcomas, mastocytosis</p>
<p class="tbodyh">Atrial myxomas: obstruction, embolism, constitutional symptoms</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Misc ~20%</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Drug fever</b>, factitious, DVT/PE, hematoma</p>
<p class="tbodyh">Thyroiditis or thyroid storm, adrenal insufficiency, pheochromocytoma</p>
<p class="tbodyh">Granulomatous hepatitis (many causes), <b class="calibre7">sarcoidosis</b>, Kikuchi’s, Behçet’s</p>
<p class="tbodyh">Familial Mediterranean fever (peritonitis, episodic fever, pleuritis; ↑ WBC &amp; ESR during attacks); other defects in innate immunity</p></td>
</tr>
</tbody>
</table>
<p class="tfn">More common causes boldfaced</p>
<p class="h">Workup <span class="r1">(</span><span class="r2">Archives</span> <span class="r1">2009;169:2018;</span> <span class="r2">AJM</span><span class="r1"> 2015;128:1138)</span></p>
<p class="noindent1">• Initial: CBC w/ diff, CMP, ESR, CRP, 3 sets BCx (off abx), U/A, UCx, CXR</p>
<p class="noindent1">• Additional workup based on sx: ANA, RF, cryoglobulin, LDH, CK/aldolase, SPEP, TFTs, PPD or IGRA, HIV Ag/Ab ± PCR, RPR, EBV serologies, CMV PCR, HBV/HCV serologies</p>
<p class="noindent1">• Consider imaging: chest &amp; abd CT, tagged WBC scan, FDG-PET, TTE, LE duplex US</p>
<p class="noindent1">• Tissue dx: consider bx of LN (excisional preferred), liver (especially if ↑ Aϕ), TA (for GCA), BM, kidney (RPGN)</p>
<p class="h">Treatment</p>
<p class="noindent1">• Empiric abx <i class="calibre6">not</i> indicated (unless Pt neutropenic or critically ill)</p>
<p class="noindent1">• Empiric glucocorticoids not indicated unless strong suspicion for specific rheumatologic dx</p>
<p class="noindent1">• Stop unnecessary meds (only 20% with a med cause have eos or rash)</p>
<p class="noindent1">• Up to 30% of cases remain undiagnosed, most spontaneously defervesce (wks to mos)</p>
<p class="h1cr">F<small class="calibre31">EVER</small> <small class="calibre31">AND</small> R<small class="calibre31">ASH</small></p>
<p class="h">Approach to diagnostic workup</p>
<p class="noindent1">• <i class="calibre6">Meningococcemia, endocarditis, RMSF, sepsis, &amp; toxic shock need urgent dx &amp; Rx</i></p>
<p class="noindent1">• Workup: CBC w/diff, BMP, LFTs, LDH, CK, U/A, HIV Ag/Ab ± PCR, BCx (off abx)</p>
<p class="noindent1">• To narrow Ddx: characterize time course of rash, progression, &amp; morphology</p>
<p class="noindent1">• <b class="calibre7">Erythema multiforme</b>: symmetric “target” lesions often of palms, soles, &amp; mucous memb</p>
<p class="noindent2"><i class="calibre6">Infxn etiol:</i> HSV, <i class="calibre6">Mycoplasma</i>, syphilis, VZV, EBV, CMV, adenovirus, etc.</p>
<p class="noindent2"><i class="calibre6">Non-infxn etiol:</i> most likely meds (eg, NSAIDs, sulfa, AEDs), autoimmune disease</p>
<p class="noindent1"><a id="page_6-24" class="calibre4"></a>• <b class="calibre7">Erythema nodosum</b>: tender erythematous or violaceous nodules usually symmetric on LE</p>
<p class="noindent2"><i class="calibre6">Infxn etiol: Strep</i>, TB, EBV, <i class="calibre6">Bartonella</i>, HBV, psittacosis, fungal, <i class="calibre6">L. venereum</i>, etc.</p>
<p class="noindent2"><i class="calibre6">Non-infxn etiol:</i> sarcoidosis, IBD, Behçet’s, other rheum, pregnancy/OCP use</p>
<p class="noindent1">• Pursue specific dx based on exposure hx &amp; exam, including serologies, viral PCRs, possibly skin biopsy ± exam of vesicular or bullae fluid if present</p>
<p class="noindent1">• Immunosupp. Pts need broad w/u; higher risk of disseminated/rapidly progressive infxns</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre18"/>
<col class="calibre13"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Variable</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Possible Etiology</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Summer/fall &gt; other seasons</p></td>
<td class="th1"><p class="tbody">Enterovirus</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Winter</p></td>
<td class="th1"><p class="tbody">Parvovirus, Meningococcemia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Spring/summer</p></td>
<td class="th1"><p class="tbody">Lyme, RMSF, Ehrlichiosis, Anaplasmosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Year-round</p></td>
<td class="th1"><p class="tbody">Adenovirus, <i class="calibre6">Mycoplasma</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cat and dog exposure</p></td>
<td class="th1"><p class="tbody"><i class="calibre6">Bartonella, Pasteurella, Toxoplasma, Capnocytophaga</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Tick exposure</p></td>
<td class="th1"><p class="tbody">Lyme, RMSF, Ehrlichiosis, Anaplasmosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Adult &lt;30 y</p></td>
<td class="th1"><p class="tbody">Mononucleosis (EBV or CMV)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Inadequate immunization</p></td>
<td class="th1"><p class="tbody">Measles, Rubella, VZV, influenza</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Sexually active</p></td>
<td class="th1"><p class="tbody">HIV, syphilis, disseminated gonococcal infection, HSV</p></td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th1"><p class="tbody"><b class="calibre7">Consider noninfectious causes</b>: allergy/DRESS, DVT, phlebitis, vasculitides, neutrophilic dermatoses, gout, connective tissues dis., malignancy, foreign body rxn</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment</p>
<p class="noindent1">• Empiric abx <i class="calibre6">not</i> indicated (unless Pt neutropenic or critically ill)</p>
<p class="noindent1">• Consider important empiric isolation precautions (ie, varicella → airborne/contact; measles → airborne; meningococcus → droplet) while workup pending</p>
<p class="h1cr">F<small class="calibre31">EVER</small> <small class="calibre31">IN</small> <small class="calibre31">A</small> R<small class="calibre31">ETURNED</small> T<small class="calibre31">RAVELER</small></p>
<p class="center"><i class="calibre6">See <a href="http://CDC.gov/travel" class="calibre4">CDC.gov/travel</a> for up to date information on regional risks and recommendations</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre18"/>
<col class="calibre13"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Region or Exposure</b></p></td>
<td class="th"><p class="tbodyh"><b class="calibre7">Common Etiologies</b> <span class="sm">(<i class="calibre6">NEJM</i> 2017;376:548)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Sub-Saharan Africa</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Malaria</b> &gt;&gt; dengue and other arboviruses, rickettsial disease, enteric fever</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">South/Southeast Asia</p></td>
<td class="th1"><p class="tbodyh">Dengue &gt; malaria, enteric fever (<i class="calibre6">S. typhi/paratyphi</i>), Chikungunya and other arboviruses</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Central &amp; S. America</p></td>
<td class="th1"><p class="tbodyh">Dengue, enteric fever, malaria</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Caribbean &amp; Mexico</p></td>
<td class="th1"><p class="tbodyh">Dengue &gt;&gt; Chikungunya and other arbovirsuses &gt; enteric fever, malaria</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Middle East</p></td>
<td class="th1"><p class="tbodyh">Middle East Respiratory Syndrome, brucellosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Freshwater swimming</p></td>
<td class="th1"><p class="tbodyh">Schistosomiasis, leptospirosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Unpurified drinking water</p></td>
<td class="th1"><p class="tbodyh">Enteric disease (<i class="calibre6">E. coli</i> &gt;&gt; <i class="calibre6">S. typhi</i>, <i class="calibre6">Campylobacter</i>, hepatitis E &gt; <i class="calibre6">Vibrio cholerae</i>), amoebic liver abscess</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Lacking immunizations</p></td>
<td class="th1"><p class="tbodyh">HAV/HBV, <i class="calibre6">S. typhi</i>, influenza, measles, rubella, yellow fever</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Pts visiting friends and relatives abroad are most likely to contract illness during travel</p>
<p class="noindent1">• Also consider domestic infxns, influenza, STIs, &amp; non-infxn causes</p>
<p class="h">Select clinical manifestations</p>
<p class="noindent1">• <b class="calibre7">Ebola:</b> fever in traveler from area with active transmission of Ebola w/in 21 d</p>
<p class="noindent1">• <b class="calibre7">Malaria:</b> nonspecific sx including diarrhea, headache, myalgias, cough, Δ MS</p>
<p class="noindent1">• <b class="calibre7">Dengue:</b> nonspecific sx including headache, severe myalgias, rash/petechiae</p>
<p class="noindent1">• <b class="calibre7">Chikungunya:</b> nonspecific sx including joint pain, moderate myalgias</p>
<p class="noindent1">• <b class="calibre7">Typhoid</b> <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;385:1136)</span>: diarrhea/constipation, abd pain, ± rash, relative bradycardia</p>
<p class="noindent1">• <b class="calibre7">Rickettsial disease:</b> headache, myalgias, lymphadenopathy, ± rash/eschar</p>
<p class="noindent1">• <b class="calibre7">Zika:</b> rash, arthralgia, headache, conjunctivitis; often less severe than dengue, Chikungunya</p>
<p class="h">Workup</p>
<p class="noindent1">• Routine testing: CBC w/ diff, BMP, LFTs, BCx, UA, rapid malaria test</p>
<p class="noindent1">• <b class="calibre7">Fever in a traveler from a malaria zone is malaria until proven otherwise; consider a medical emergency → hospitalization &amp; empiric Rx.</b> One ⊖ smear does <i class="calibre6">not</i> r/o.</p>
<p class="noindent1">• Other tests based on s/s, labs, exposure, incubation period, geography, and seasonality. O&amp;P exam, CXR, blood smears for filaria/Babesiosis/<i class="calibre6">Borrelia</i>, serologies, STI &amp; HIV, PPD or IGRA, bone marrow aspirate, bx of lymph nodes or skin lesions, CSF studies.</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0011.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0013.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
